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ABSTRACT
The Effect of Cocoa Flavanols on β-Cell Mass and Function
Thomas John Rowley
Department of Nutrition, Dietetics, and Food Science, BYU
Master of Science
A hallmark of type 2 diabetes (T2D) is β-cell dysfunction and the eventual loss of
functional β-cell mass. Therefore, mechanisms that improve or preserve β-cell function could be
used to improve the quality of life of individuals with T2D. Studies have shown that monomeric,
oligomeric and polymeric cocoa flavanols have different effects on obesity, insulin resistance
and glucose tolerance. We hypothesized that these cocoa flavanols may have beneficial effects
on β-cell function. INS-1 832/13 derived β-cells and primary rat islets cultured with a
monomeric catechin-rich cocoa flavanol fraction demonstrated enhanced glucose-stimulated
insulin secretion, while cells cultured with total cocoa extract, oligomeric, or polymeric
procyanidin-rich fractions demonstrated no improvement. The increased glucose-stimulated
insulin secretion in the presence of the monomeric catechin-rich fraction corresponded with
enhanced mitochondrial respiration, suggesting improvements in β-cell fuel utilization.
Mitochondrial complex III, IV and V components were upregulated after culture with the
monomer-rich fraction, corresponding with increased cellular ATP production. The monomerrich fraction improved cellular redox state and increased glutathione concentration, which
corresponds with Nrf2 nuclear localization and expression of Nrf2 target genes, including NRF-1
and GABPA, essential genes for increasing mitochondrial function. We propose a model by
which monomeric cocoa catechins improve the cellular redox state, resulting in Nrf2 nuclear
migration and upregulation of genes critical for mitochondrial respiration, and, ultimately,
enhanced glucose-stimulated insulin secretion and β-cell function. These results suggest a
mechanism by which monomeric cocoa catechins exert their effects as an effective
complementary strategy to benefit T2D patients.
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Abstract
Dietary administration of cocoa flavanols may be an effective complementary strategy for
alleviation or prevention of metabolic syndrome, particularly glucose intolerance. The complex
flavanol composition of cocoa provides the ability to interact with a variety of molecules, thus
allowing numerous opportunities to ameliorate metabolic diseases. These interactions likely
occur primarily in the gastrointestinal tract, where native cocoa flavanol concentration is high.
Flavanols may antagonize digestive enzymes and glucose transporters, causing a reduction in
glucose excursion, which helps patients with metabolic disorders maintain glucose homeostasis.
Unabsorbed flavanols, and ones that undergo enterohepatic recycling, will proceed to the colon
where they can exert prebiotic effects on the gut microbiota. Interactions with the gut microbiota
may improve gut barrier function, resulting in attenuated endotoxin absorption. Cocoa may also
positively influence insulin signaling, possibly by relieving insulin-signaling pathways from
oxidative stress and inflammation and/or via a heightened incretin response. The purpose of this
review is to explore the mechanisms that underlie these outcomes, critically review the current
body of literature related to those mechanisms, explore the implications of these mechanisms for
therapeutic utility, and identify emerging or needed areas of research that could advance our
understanding of the mechanisms of action and therapeutic potential of cocoa flavanols.

Keywords: Epicatechin; Procyanidins; Diabetes; β-Cells; GLP-1; Endotoxin
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1. Introduction

1.1. Metabolic syndrome
Metabolic syndrome is a cluster of related conditions that increases an individual's risk for
developing cardiovascular disease and Type 2 diabetes mellitus (T2DM) [1,2]. The components
of metabolic syndrome include abdominal obesity, dyslipidemia, elevated blood pressure, insulin
resistance, glucose intolerance, β-cell loss, low-grade chronic inflammation and a prothombotic
state [1–3]. The prevalence of obesity, cardiovascular disease and diabetes has been increasing in
the United States and worldwide for the past several decades. Approximately one in ten adults in
the United States has diabetes, one in three has a cardiovascular disease and one in three is obese
[4,5]. Many individuals with metabolic syndrome will progress to the full expression of these
diseases. The prevalence of metabolic syndrome is now greater than 34% in the U.S. [6].
Increasing attention has been directed toward finding novel strategies to prevent, slow the onset
and/or progression of and potentially reverse metabolic syndrome [7].
1.2. Flavanols and metabolic syndrome
Dietary flavanols offer an interesting potential complementary strategy that may improve this
complex, multifaceted syndrome. First, flavanols may help reduce glucose excursion by slowing
digestion and enhancing the incretin response. Second, flavanols may help reduce systemic
endotoxin exposure via improvement in gut barrier function. While flavanols from a variety of
dietary sources appear promising, cocoa flavanols represent an emerging approach for
intervention in metabolic syndrome. Following an overview of polyphenols, this review will
focus on flavanols found in cocoa. Cocoa bioavailability will be briefly reviewed, followed by a
summary of the primary research utilizing cocoa, and lastly, the hypothesized mechanisms by
which cocoa flavanols improve metabolic syndrome will be discussed.
3

2. Cocoa flavanols

2.1. Flavanols
Polyphenols are secondary metabolites found ubiquitously in plants. One prominent subclass of
polyphenols is the flavonoids. The basic flavonoid skeleton consists of two benzene rings linked
by a 3 carbon heterocyclic (O-containing) ring. Flavonoids are further divided into subclasses
based on the nature of the heterocyclic ring and substituents: flavanols, flavonols, flavones,
flavanones, isoflavones and anthocyanins [8]. Flavanols are hydroxylated at C3 in the
heterocyclic ring and are thus sometimes referred to as flavan-3-ols. This hydroxyl group may be
modified by an addition of a gallate group. Flavanols may exist as monomers, or as
oligomers/polymers [with various degrees of polymerization (DP)] comprised of flavanol
monomer residues (known as proanthocyanidins). Major dietary flavanol monomers include (+)catechin (+ C), (−)-catechin (− C), (−)-epicatechin (EC) and others. Cocoa is unique in that it is
the only significant dietary source of − C. Procyanidins (PCs, as opposed to prodelphinidins)
specifically refer to proanthocyanidins with predominantly catechin and epicatechin monomer
residues [9]. Although largely beyond the scope of this review, PCs may also contain either Aor-B-type linkages [10]. Cocoa, the focus of this review, contains PCs with B-type linkages.
2.2. Dietary sources of flavanols
Significant levels of flavanols are found in a variety of dietary plants including tea, apples,
grapes, cocoa, berries, plums, apricots and nuts [9,11–13]. The flavanol content is higher in
certain foods such as grapes, tea and cocoa, compared to other plants, and thus the body of
literature focuses on these products. Cocoa is generally regarded as the most concentrated dietary
source of flavanols with the strongest antioxidant potential [7,14].
4

Although many potentially bioactive compounds are found in cocoa, many of the health benefits
associated with its consumption are likely due to its high flavanol content. Cocoa is composed of
flavanol monomers, oligomers, and polymers [15]. The most common monomers found in cocoa
are epicatechin (up to 35% of polyphenol content) [16,17], as well as (±)-catechin. It is important
to note that cocoa is one of the few foods with appreciable levels of (−)-catechin, which is
produced by epimerization of (+)-catechin during fermentation. Cocoa contains PCs composed
of up to 12 monomeric residues [18], although larger species likely exist but are not easily
measured by common chromatographic methods. There can be great variability in cocoa phenol
content from Theobroma cacao plants of different origins [16] and the polyphenol content of
cocoa powder is largely dependent on processing methods.
The impacts of tea and grape seed on metabolic syndrome have been extensively reviewed and
analyzed [19–22]. Furthermore, there is a large body of literature regarding the effects of cocoa
on cardiovascular disease [23–25]. However, the potential link between cocoa and improvements
to metabolic syndrome and, specifically, glucose homeostasis and diabetes is a newer, lessstudied area and warrants further investigation and a review of the current literature. Therefore,
this review focuses specifically on the potential mechanisms by which cocoa flavanols improve
metabolic syndrome, particularly glucose homeostasis and diabetes.
2.3. Bioavailability of cocoa flavanols
Understanding flavanol bioavailability is critical for identifying flavanol bioactivities [13].
Bioavailability of cocoa flavanols from food is a multistep process including digestion and
release of flavanol from its food matrix, solubilization and absorption into enterocytes,
xenobiotic metabolism in the enterocytes, liver and colon and, lastly, elimination [26]. While an
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exhaustive discussion of flavanol bioavailability is beyond the scope of this review, unique
aspects of cocoa flavanol bioavailability warrant mention as they pertain to mechanism.
Potential PC instability during gastric transit has been suggested as a factor limiting
bioavailability of orally administered flavanols. PCs could be hydrolyzed to form monomers (or
partially hydrolyzed to form monomers and smaller PCs) in the low pH conditions of gastric
juice. Spencer et al. [27] reported that PC oligomers (up to DP 6) were degraded to monomeric
flavanol residues when incubated in an acidic solution (pH ~ 2.0) for up to 3.5 h. However, there
are conflicting reports on this phenomenon in both animals and humans [28–33]. Tsang et al.
[30] found that polyphenols from grape seed extract (catechin, epicatechin PC dimers, trimers
and tetramers) were intact in the GI tract after an oral gavage in Sprague–Dawley rats. They
concluded that there was neither a sizeable increase in monomers nor a concomitant decrease in
oligomers, suggesting that the oligomers were stable through gastric transit [30]. Rios et al. [28]
reported that PCs were intact after being ingested with a meal in humans. After participants
drank a 500-ml cocoa beverage, the pH of the stomach was elevated, keeping the cocoa powder
protected from an extremely acidic environment (such as the environment utilized in the study
conducted by Spencer et al. [27]). Further, the in vivo study showed that the 500-ml beverage
was emptied from the stomach in about 50 min, whereas the incubation study lasted up to 3.5 h
[28]. Therefore, it appears that PCs, as well as monomeric flavanols, remain intact during gastric
transit. Some depolymerization may occur, but the amount is so small that any increase in
monomer concentration would be negligible [9,30]. Therefore, gastric degradation is unlikely to
limit flavanol bioavailability and bioactivity.
Bioavailability is thought to reduce potential flavanol bioactivity in vivo. Monomers (catechin
and epicatechin) are relatively well absorbed compared to PCs [28,34,35]. They first appear in
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the circulation 30–60 min after ingestion [36] and reach peak plasma concentrations at 2–3 h
[28]. Epicatechin appears in greater concentrations in human plasma than catechin. Holt et al.
[37] reported that there is a preferential absorption of epicatechin. When catechin and
epicatechin were given to participants in equal concentrations, there was 5.92-μM epicatechin
but only 0.16-μM catechin in the plasma 2 h after ingestion [37]. Furthermore, the (+)-catechin is
more bioavailable than (−)-catechin, which predominates in fermented cocoa [38]. Dimeric,
trimeric and tetrameric PCs are also absorbed in their intact form but at a much lower rate
compared to the monomers [9]. Interestingly, Deprez et al. [39] showed that (+)-catechin and PC
dimers and trimers had similar permeability coefficients as mannitol (an indicator of paracellular
transport) in Caco-2 monolayers. Therefore, these smaller flavanols are likely entering the
bloodstream via paracellular diffusion [39,40]. Polymers larger than tetramers are generally not
absorbed intact [9] and proceed to the colon, along with unabsorbed fractions of monomers and
smaller PCs. Approximately 5–10% of polyphenols can be absorbed in the small intestine while
the remaining 90–95% proceed to the colon [41]. Poor PC bioavailability therefore is likely a
main factor that limits bioactivity in peripheral tissues, particularly for larger PCs. Their
relatively low bioavailability indicates that the gut may be the primary location of action for
cocoa PCs due to the high concentrations present there compared to levels in circulation [9,42].
Concentrations of flavanols in the blood and tissues are typically less than 5 μM [37,43–45],
which are at the lower end of concentrations typically used in vitro to asses bioactivity in cell
models [46]. However, when the intestinal lumen or epithelial surface is the site of action (such
as inhibition of digestive enzymes or absorption transporters, modulation of gut barrier integrity,
etc.), bioavailability is not a limiting factor.
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Flavanols are degraded in the colon by the gut microbiota, and some of the resulting metabolites
can then be absorbed into the circulation. The conversion of (+)-catechin to (+)-epicatechin is a
prerequisite step for microbial metabolism [47]. These monomers are typically metabolized to
form 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone, 5-phenyl-γ-valerolactone and phenylpropionic
acid [47]. The majority of cocoa PCs are degraded into many metabolites, including phenolic
acids and phenylvalerolactones [9,18,48,49], and possibly others that have not been identified.
As PCs increase in size, the ability of bacteria to metabolize them decreases [50]. Gonthier et al.
[51] found that the yield of phenolic acids from monomers and PC dimers (10% and 7%) was
much greater than those from PC trimers and polymers (0.7% and 0.5%).
Microbial metabolites of flavanols should be considered as potential contributors to the health
effects of these compounds observed following oral administration [41,52], as they are
extensively produced and comparatively more bioavailable [53,54] than the native compounds
themselves (particularly the PCs). Despite general recognition that these microbial metabolites
are likely to contribute extensively to the activities observed during consumption of flavanols
(and polyphenols in general) [55–57], very little is known about the bioactivities of these
compounds. In terms of glucose homeostasis, Fernandez-Millán et al. [58] showed that 3,4dihydroxyphenylacetic acid, 2,3-dihydroxybenzoic acid and 3-hydroxyphenylpropionic acid
potentially improve glucose-stimulated insulin secretion and resistance to oxidative stress in βcells and rat islets. Carrasco-Pozo et al. [59] recently demonstrated that 3,4
dihydroxyphenylacetic acid protected β-cells against impaired insulin secretion, mitochondrial
dysfunction and increased apoptosis induced by cholesterol. These metabolites are also known to
have antiinflammatory effects [52,60]. Therefore, these microbial metabolites appear to have
significant activities related to improving glucose homeostasis, but only a few of the dozens of
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compounds have been investigated, and the impact of these metabolites in most tissues critical to
glucose homeostasis remains unstudied. To the best of our knowledge, no published data exist
regarding the potential impacts of these metabolites on skeletal muscle, adipose tissue or liver
physiology and metabolism. In vitro tissue culture experiments are needed in order to determine
the impacts of microbial metabolites on pathways related to glucose homeostasis in these tissues.
The majority of research has focused on characterizing the formation, bioavailability and
pharmacokinetics of these metabolites. Few studies have examined the activities of the microbial
metabolites directly, likely due to several reasons. First, not all microbial metabolites are
commercially available [49,61]. Second, in order to test compounds that are not commercially
available, in vitro or in vivo fecal fermentations must be performed and the desired product(s)
extracted, isolated and purified from a complex mixture of several dozen native and metabolite
compounds and then characterized analytically. The complexity, time, cost and low yields
associated with this process can be prohibitive. Third, some microbial metabolites are highly
transient [49], particularly the intermediate products which are subsequently converted into
smaller products. Thus, these compounds are even more difficult to isolate. Fourth, the large
number of metabolites makes screening of these compounds for biological activity laborious.
Finally, in vivo testing of these compounds is difficult, as they are formed only in the lower gut.
Therefore, studies involving direct oral administration of these metabolites are problematic, as
activities in the stomach and small intestine (as well as absorption from those regions) are likely
to be observed despite being irrelevant to activities resulting from colonic formation of the
metabolites. One solution is to observe the activities of metabolites by eliminating them: native
flavanols could be fed to both normal animals and either germ-free or antibiotic-fed animals, and
the differences in activities are likely associated with the microbial metabolites. Due to this issue,
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in vitro cell culture studies are currently the most promising and urgently needed aspect of
understanding how these metabolites contribute to the health benefits of flavanol consumption.
Specifically, studies are needed which examine the activities in β-cells (insulin secretion,
proliferation, apoptosis, resistance to oxidative stress), intestinal L-cells (incretin hormone
secretion), hepatocytes (gluconeogenesis, lipid accumulation), skeletal muscle (insulin
sensitivity, metabolic flexibility, mitochondrial function, lipid accumulation) and adipocytes
(differentiation, lipid accumulation, hormone secretion). These activities may represent major
mechanisms by which orally consumed cocoa flavanols exert their activities. Of all the
mechanisms described in this review, this is the least investigated area and the area in which
relevant data are most urgently needed. Therefore it is possible that the potential activities of
microbial metabolites are the area in which the greatest advances in knowledge stand to be
gained.

3. Animal and clinical studies

Prior to reviewing mechanisms of action, we summarize outcomes of relevant animal and human
studies to identify the impact of cocoa and cocoa flavanols on metabolic syndrome.
3.1. Animal studies
Many animal studies have been conducted to examine whether cocoa may reduce circulating
endotoxin, oxidative stress and inflammation and, thus, improve glucose control and other
outcomes related to metabolic syndrome. These studies are summarized in Table 1. The studies
listed are mostly chronic studies, lasting anywhere from 1 to 18 weeks [62,63], and there were
only two acute studies [64,65]. Many rodent models mimicking diabetes or prediabetes were
utilized, and many of the studies utilized high-fat diets. Many of these studies reported
10

improvements in glucose-related outcomes (fasting glucose levels as well as glucose tolerance)
[17,64,66–72], while three studies reported no changes [63,73–75]. One study reported changes
in gut microbiome [76], and two studies reported attenuated endotoxin levels [17,63].
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Table 1
Author, year

Animal
model

Treatment/Delive
ry

Matsui,
2005 [225]

Male Wistar
rats

Ruzaidi,
2005 [66]

Male diabetic
Wistar rats,
(STZdinduce
d)

12.5% (w/w)
cocoa powder, in
food
1, 2, 3% (w/w)
cocoa extracte, in
food

Tomaru,
2007 [67]

Female,
db/db mice
(obese,
diabetic)

Jalil, 2008
[158]

Male ob/db
Sprague–
Dawley rats
(STZ
induced)
Male ob/db
Sprague–
Dawley rats
(STZ
induced)

Jalil, 2009
[68]

Animal
dose
(mg/kg
body
weight)
7,040b

Human
equivalent
dosea(mg/da
y)

Acute/Chron
ic design,
diet

Cocoa treatment
outcomes

79,913c

Diabetic
ratsf:
1% =
868
2% =
1,776
3% =
2,580
Normal
Rats:
1% =
433
2% =
860
3% =
1,200
0.5% =
1,107g
1.0% =
2,044

Diabetic rats:
1% = 9,853
2% = 20,160
3% = 29,286
Normal rats:
1% = 4,919
2% = 9,762
3% = 13,622

Chronic, 3
weeks, highfat diet
Chronic, 4
weeks,
normal diet

↓ final body
weights, ↓ fatty
acid synthesis
↓ glycemia, ↓
hypercholestere
mia

0.5% =
5,771
1.0% =
11,602

Chronic, 3
weeks,
normal diet

↓ blood glucose
in a dose
dependent
manner

600

6,811

Chronic, 4
weeks, highfat diet

↓ oxidative stress
(8-isopostane)

Cocoa extract, by
oral gavage

600

6,811

Chronic, 4
weeks, highfat diet.

Unknow
n (food
intake
data not
reported
).
150

Unknown
(food intake
data not
reported).

Chronic, 3
weeks,
normal diet

↑ glucose
tolerance
(OGTT- AUC), ↓
total cholesterol,
↓ triglycerides.
No changes in
insulin sensitivity
↓ immune
response (IgG1,
IgG2, S-IgA) (5
and 10%
treatments)

851

Chronic, 15
weeks,
normal diet.

0.5%, 1.0%
(w/w) cacao
liquor
proanthocyanidin
, in food
Cocoa extract, by
oral gavage

PerezBerezo,
2011 [242]

Female
Wistar rats

2%, 5%, or 10%
(w/w) cocoa
powder, in food

Si, 2011
[73]

Male db/db
mice

0.25%
epicatechin, in
drinking water

↓ inflammatory
markers (CRP,
IL1B), oxidative
stress (GSH,
SOD), ↑ lifespan.
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MassotCladera,
2012 [76]

Female
Wistar rats

10% (w/w) cocoa
powderh, in food

Yamashita,
2012 [243]

Male
C57BL/6
mice

0.5, 2.0% (w/w)
cacao liquor
procyanidinsi, in
food

Yamashita,
2012 [62]

Male
C57BL/6
mice

0.5%, 1% (w/w)
cocoa liquor
procyanidins, in
food

Yamashita,
2012 [62]

Male
ICRkmice

Cocoa liquor
procyanidins, by
oral gavage

de Oliveira,
2013 [74]

Male Wistar
STZ-induced
diabetic rats

Yamashita,
2013 [64]
Dorenkott,
2014 [17]

Gu, 2014
[75]

no change in
glycemia
Altered gut
microbiome (↓
Bacteroides,
Staphylococcus,
Clostridium)

Unknow
n (food
intake
data not
reported
).
Normal
dietj:
0.5% =
588
2.0% =
2,344
High-fat
diet:
0.5% =
310
2.0% =
1,532
Unknow
n (food
intake
data not
reported
).
50 or
250

Unknown
(food intake
data not
reported).

Chronic, 6
weeks,
normal diet.

Normal diet:
0.5% =
3,337
2.0% =
13,304
High-fat
diet:
0.5% =
1,759
2.0% =
8,695

Chronic, 13
weeks,
control or
high-fat diet

↓ fasting glucose
(2.0% treatment);
↑ glucose
tolerance (OGTT
AUC). ↑
translocation of
GLUT4, AMPK
phosphorylation,
UCP expression

Unknown
(food intake
data not
reported).

Chronic, 1
week,
normal diet

↑ glucose
tolerance in a
dose dependent
manner (OGTTAUC)

283 or 1,418

Acute

Cocoa liquorl, by
oral gavage

3,600 or
7,200

1,157 or
2,317

Chronic, 40
days, normal
diet

Male ICR
mice
Male
C57L/l6 mice

Procyanidins, by
oral gavage
Monomeric,
oligomeric and
polymeric cocoa
extract fractions,
in food

0.01

0.06

Acute

25

142

Chronic, 12
weeks, highfat diet

High fat-fed
obese male
C57BL/6 J
mice

8% (w/w) cocoa
powder, in food

11,828m

67,135

Chronic, 10
weeks, highfat diet

↑ glucose
tolerance
(OGTT-AUC)
(250-mg/kg
dose)
↑ antioxidant
capacity (ORAC,
FRAP), no
change in blood
glucose levels
↑ plasma insulin;
↑ GLP-1 levels
Oligomeric
fraction ↓ fasting
blood glucose, ↑
glucose
tolerance; ↑
insulin tolerance
(OGTT); ↓
endotoxin
↓ weight gain, ↑
fecal lipid
content, ↑ insulin
sensitivity
(HOMA-IR), ↓
inflammatory
markers (IL6,MCP-1), no

13

Gu, 2014
[63]

Male
C57BL/6 J
mice

8% (w/w) cocoa
powder, in food

4,998n

28,367

Chronic, 18
weeks, highfat diet

GutierrezSalmean,
2014 [190]

High fat-fed,
obese, male
Wistar rats

(−)-epicatechin,
by gavage

1

11

Chronic, 2
weeks, low
fat or highfat diet

GutierrezSalmean,
2014 [72]

Male Wistar
rats

(−)-epicatechin,
by gavage

1

11

Matsumura,
2014 [65]

Male ICR
mice

Flavanol fraction
or (−)epicatechin, by
gavage

10

57

Chronic, 2
weeks, low
fat or highfat diet
Acute

Osakabe,
2014 [3]

Male Wistar
rats

0.2% (w/w)
flavanols, in food

78

890

Papadimitro
u, 2014
[227]

Male
SHRorats,
diabetic (STZ
induced)
Male
C57BL/J
mice

Cocoa powder,
by gavage

24

272

Cocoa flavanolsp
by gavage

50

284

Watanabe,
2014 [70]

Chronic, 4
weeks, highfat diet
Chronic, 16
weeks,
normal diet

change in blood
glucose
↓ inflammation
(adipose tissue
NF-κB
expression), ↑
insulin sensitivity
(HOMA-IR), ↑
gut barrier
function (plasma
GLP-2), ↓
plasma endotoxin
↓ blood glucose,
↓ triglyceride
levels, ↑
mitochondrial
function (TFAM,
mitofilin
expression)
↓ fasting glucose;
↑ glucose
tolerance.
Flavanol fraction
↑ energy
expenditure
(REE), ↑ blood
catecholamines
↓ thermogenesis,
↓ lipolysis
AMPK, ↓ NOX4
signaling

↓ plasma
glucose. ↓ resting
energy
requirements,
mitogenesis
FernandezMale Zucker
10% (w/w) cocoa 8,311q
94,345
Chronic, 9
Prevented B cell
Millan,
diabetic fatty powder, in food
weeks,
mass loss, ↑
2015 [71]
rat
normal diet
glucose tolerance
(OGTT) insulin
sensitivity
(HOMA-IR), ↑ β
cell function
(HOMA-B), ↓
oxidative stress
(carbonyl groups,
TBARs)
Human equivalent doses were calculated by the equation provided by Reagan-Shaw et al. [241] using food intake
and body weight data, if provided. Assumptions made for calculation are indicated in the footnotes.
a

Chronic, 2
weeks,
normal diet

Based on a 70 kg human.
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b

Used reported final body weight to calculate animal and human equivalent doses.

c

Author reported 50,000 mg/70 kg/day human equivalent dose.

d

Streptozotocin.

e

285.6 mg polyphenols/g extract.

f Assumed body weights of rats were 0.30 kg for normal rats and 0.25 kg for diabetic rats, based on reported
body weights, to calculate animal and human equivalent doses.
g Average food intake and body weights during weeks 4–6 were used to calculate animal and human
equivalent doses.
h

Cocoa powder contains 10.62-mg/g polyphenols.

i

Cocoa liquor procyanidin contained 69.8% polyphenols.

j Based on body weights at the end of the experiment and total food intake averaged over the entire
experiment.
k

Institute of Cancer Research/Imprinting Control Region mouse.

l

Total phenolics 2845-mg/100 g dry weight.

m Based on average weight at the start of the experiment (0.020 kg mouse) and does not account for weight
gained during the experiment, since final weights not provided (only displayed in graph).
n Based on average final weights (0.0471-kg mouse).
o

Spontaneously hypertensive rat.

p

Flavanol fraction was 72.4% w/w total polyphenols.

q

Based on final weight (0.2335-kg rat) and average food intake (19-g food/day) over 10 weeks.
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When evaluating these studies, it is important to note the experimental procedures by which
cocoa was given to the animals. There was a wide range of doses used as well as a variety of
dosing methods (discussed in more detail below). The dosing method may impact the
mechanisms by which cocoa flavanols act in vivo. Some cocoa was available ad libitum by
adding it into the chow or the drinking water. In this case, flavanols were co-consumed with
macronutrients, thereby facilitating flavanol-mediated alteration of nutrient digestion. This cocoa
supplement was often reported as a percentage of food (w/w) or water (w/v). Other studies
supplemented the cocoa by means of an oral gavage, and these doses were often reported as a
dose in mg/kg body weight. Oral gavage is often done in the fasted state, in which case flavanols
would not be co-consumed with macronutrients, thereby precluding the opportunity for flavanolmediated alteration of nutrient digestion. While each procedure had its advantages, it is
important to note the differences between the two. When cocoa was provided ad libitum, the
dose was dependent on food intake, which was sometimes not reported. Cocoa is extremely
bitter, and high percentages of cocoa may have been unpalatable and therefore led to a reduced
food intake, possibly contributing to the observed positive outcomes. This is a potential
mechanism of action in animal studies that is not likely translatable to humans. Further, studies
comparing high-fat diets to normal diets (each with cocoa supplements) [69] had significantly
different food intakes, meaning different doses of cocoa were being ingested. Studies comparing
normal animals to diabetic animals [66,67] also had the same dilemma. In studies using diabetic
rats, there were also significant differences in food intake, where the diabetic animals ate more
and therefore were consuming more polyphenols.
Another aspect of study design to consider when evaluating the effective dose and potentially
bioactive constituents of cocoa is the different types of cocoa product utilized. Animal studies
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have used cocoa liquor (liquefied cocoa mass), chocolate (cocoa liquor + sugar and possibly
other ingredients), cocoa powder (cocoa liquor with most of the cocoa butter removed), cocoa
extracts (prepared by distinct extraction procedures, containing various profiles of phenolic
acids, flavanols, etc.) and pure compounds (catechins, epicatechin, etc.). These all have different
amounts of fiber, lipids and polyphenols, all of which may possess beneficial activities that may
have synergistic, or even antagonistic, effects with flavanols. While the majority of studies show
efficacy, these confounding components make interpretation of the effective dose problematic.
These non-flavanol components may act by mechanisms distinct from the flavanols. On the other
hand, purified compounds alone are not representative of the complexity of cocoa products.
While most studies show some efficacy of these various cocoa products, studies are still needed
to isolate the activities of individual components. For example, the effect of flavanols versus
nonflavanol components could be elucidated by comparing the impact of cocoa versus an
equivalent dose of heavily Dutched cocoa. Furthermore, cocoa could be deconstructed by
sequentially extracted cocoa lipids (with hexane) and then flavanols (with acetone:water:acetic
acid), leaving fiber and other insoluble components. The various fractions could then be
compared against whole cocoa, or cocoa minus specific components, to elucidate the role of each
component. When evaluating the potential translational benefits to humans, it should be
understood that humans generally consume chocolate, cocoa powder and cocoa liquor (in solid
form) and generally do not consume cocoa extracts or pure compounds (although cocoa extracts
or products with added cocoa extracts can be obtained in supplement form).
In summary, animal studies of the impacts of cocoa, chocolate, cocoa extracts or cocoa
monomers on metabolic syndrome have been highly descriptive. These studies have suggested
potential mechanisms but do not definitively isolate or interrogate the proposed mechanisms.
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3.2. Clinical studies
There have been a variety of clinical trials assessing the effects of habitual cocoa intake on
glycemic and insulinemic outcomes. These are summarized in Table 2. Many of the studies
found cocoa to be beneficial for glucose control [77–83]. Cocoa treatments were often provided
in the form of chocolate bars [78–82] or beverages [83–87]. Chronic studies lasted from 5 days
to 3 months [83,86,87], but most lasted about 2 weeks.
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Table 2
Author, year

Subjects

Health status

Nguyen, 1994
[244]

N = 10

Healthy

Brand Miller,
2003 [77]

N = 10

Healthy

Basu, 2015
[88]

N = 14

Obese, Type 2
diabetic

Grassi, 2005
[78]

N = 15

Healthy

Grassi, 2005
[79]

N = 20

Hypertensive

Muniyappa,
2008 [84]

N = 20

Hypertensive

Grassi, 2008
[80]

N = 19

Davison, 2008
[83]

N = 49

Hypertensive,
impaired
glucose
tolerance
Overweight
and obese
(BMI > 25
kg/m2)

Mellor, 2010
[89]

N = 12

Type 2 diabetic

Almoosawi,
2012 [82]

N = 42

Desideri, 2012
[85]

N = 90

Healthy (BMI
< 25 kg/m2)
compared to
overweight
(BMI > 25
kg/m2)
Mild cognitive
impairment

Treatment
(daily dose)
100-g
chocolate bar,
(45-g cocoa)
6 food pairs,
one flavored
with cocoaa

Acute/Chronic
(duration)
Acute

Cocoa
beverage (960mg
polyphenols,
480-mg
flavanolsb)
100-g
chocolate bar,
(500-mg
polyphenols)
100-g
chocolate bar,
(88-mg
flavanolsc)
150-ml
beverage, 2
×/day. (900-mg
flavanolsd)
100-g
chocolate bar,
(1008-mg
phenols)
150-ml cocoa
beverage (2
×/day), high
flavanol (902
mg) and low
flavanol (36
mg)
45-g chocolate
(3 bars/day),
(16.6-mg
epicatechine)

Acute

20-g dark
chocolate,
(500-mg
polyphenols)

Chronic (4
weeks),
crossover
design

Cocoa
beverage, (990-

Chronic (8
weeks),

Acute

Chronic (15
days),
crossover
design
Chronic (15
days),
crossover
design
Chronic (2
weeks),
crossover
design
Chronic (15
days),
crossover
design
Chronic (12
weeks),
randomized
arm

Chronic (8
weeks),
crossover
design

Outcomes
Lesser but prolonged
increase in glucose
and insulin.
↑ insulin response
(insulin index) but
not glycemic
differences with
chocolate flavored
products.
↑ postprandial insulin
secretion, no
improvements in
blood glucose or
insulin resistance
(except 4-h postmeal)
↑ insulin sensitivity
(HOMA-IR,
QUICKI), ↑ glucose
tolerance (OGTT).
↑ insulin sensitivity
(HOMA-IR,
QUICKI, ISI).
No effects on insulin
sensitivity (QUICKI
and clamp).
↑ insulin sensitivity
(HOMA-IR,
QUICKI, SI), ↑ β cell
function.
↑ insulin sensitivity
(HOMA2-IR) at 6
and 12 weeks.

No change in
glycemic control
(HOMA-IR, HbA1c,
fasting glucose). ↑
HDL cholesterol.
Treatment prevented
unfavorable changes
in insulin sensitivity
(QUICKI, HOMAIR) seen in the
placebo treatment.
High flavanol and
intermediate flavanol
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Stote, 2012
[86]

N = 19

Adults at risk
for insulin
resistance

Stellingwerff,
2013 [90]

N = 16

Trained cyclists

Haghighat,
2013 [81]
(abstract only)

N = 69

Hypertensive
diabetic adults

RamirezSanchez, 2013
[87]

N=5

mg, 520-mg or
45-mg
flavanols).

randomized
arm

Cocoa
beverage (2
×/day), (30-,
180-, 400- or
900-mg
flavanols)
Dark chocolate,
(240-mg
polyphenolsf)
25-g dark
chocolate,
(450-mg
polyphenols)
18-g cocoa
powder in a
beverage (2
×/day), (100mg
epicatechin)

Chronic (5
days),
crossover
design
Acute,
crossover
design
Chronic (8
weeks),
randomized
arm
Chronic (3
months),
parallel arm

treatments ↓ fasting
glucose, ↑ insulin
sensitivity (HOMAIR) but not fasting
insulin compared to
the low flavanol
group.
No effects on
glycemia (OGTT) or
insulinemia (HOMA,
QUICKI, ISI)
↑ Blood glucose and
↑ insulin
↓ Fasting glucose, ↓
HbA1c

T2D/Stage II
No effects on
and Stage III
glycemia/insulinemia.
heart failure
↓ oxidative stress in
patients
mitochondria.
(compared with
healthy
controls)
a Foods used include Coco Pops (Kellogg's cereal), Betty Crocker chocolate fudge super moist cake and
creamy deluxe Dark fudge frosting. Plain chocolate block (classic full cream milk chocolate from Nestle), Ultra
chocolate classic ice cream from Sara Lee and chocolate instant pudding (White Wings Foods).
b

Placebo contained 110-mg polyphenols, < 0.1-mg flavanols.

c

Consists of the flavanols: catechin, epicatechin, quercetin, kaempferol and isorhamnetin.

d

Placebo contained 14-mg flavanols.

e

Placebo contained < 2-mg epicatechin.

f

Polyphenols included epicatechin, catechin, procyanidin B2, procyanidin B5, trimer C and tetramer D.
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In select studies, cocoa and cocoa flavanols improved insulin sensitivity and reduced blood
glucose, insulin, and HbA1c in subjects with varying degrees of glucose homeostasis
(normoglycemic, prediabetic or T2DM) within 2–4 weeks [78–83,85,88]. However, other studies
showed no effect [84,86,89,90]. Despite its promising effects in vitro and in animal models, only
five chronic studies of cocoa and glucose control have been performed in subjects with
prediabetes or diabetes [78,80,81,86,89], as the majority of studies were focused on
cardiovascular or cardio-metabolic outcomes [78–81,87]. In terms of diabetes biomarkers, most
of these studies focused on insulin resistance/sensitivity; few focused on overall blood glucose
control [81,89], which is a critical clinical outcome. Furthermore, only two of these five studies
in prediabetic or diabetic subjects studies lasted > 15 d [81,89]. Neither of these two longer
studies examined prediabetes (both used subjects with existing T1/2DM) [81,89]. Therefore, the
potential for cocoa to improve long-term glucose control has not been sufficiently studied.
Additional studies lasting 1–3 months (or potentially longer) are needed. Furthermore, the
potential impact of cocoa in individuals with prediabetes has not yet been evaluated. Clinical
trials in individuals with prediabetes are thus needed in order to determine the potential utility of
cocoa for improvement of long-term blood glucose control and prevention of T2DM in this
population, where early prevention may significantly reduce or delay progression to T2DM.
Furthermore, additional studies are needed in individuals with T2DM in order to evaluate the
potential for cocoa to ameliorate T2DM and slow progression to β-cell exhaustion and failure.
Interestingly, no significant glycemic improvements were observed in the two studies that
utilized epicatechin only [87,89]. This supports the idea that the larger PCs may be important,
despite their relatively low bioavailability [17]. However, these studies [87,89] only examined
patients with prediabetes or T2DM, so health status may be an important mediator for
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interventions with epicatechin; these interventions may be more effective in healthier
individuals.
Overall, the existing clinical trials support the premise that cocoa can improve glycemic
outcomes in healthy, overweight or hypertensive adults. While many of these findings seem
promising, these studies do not provide insight into the mechanisms responsible.
Furthermore, many of these studies (and the selected primary outcomes) were related to
cardiovascular disease (generally hypertension), not glucose homeostasis/diabetes. Further, as
stated above, there have been no long-term studies examining the effects of cocoa consumption
in an at-risk (prediabetic) population, and only 5 studies in individuals with diabetes (4 examined
T2DM, while one study did not specify whether subjects were diagnosed with T1 or T2DM)
[81]. Additional studies of the mechanisms specifically related to glucose homeostasis in these
populations are greatly needed moving forward.
As with reported animal studies, human clinical studies of cocoa or chocolate have been largely
descriptive. While it is considerably more difficult to perform elegant mechanistic studies in
humans due to feasibility or ethical concerns, opportunities to move toward mechanistic studies
in humans will be discussed later in this review.

4. Potential molecular mechanisms of action

There are numerous potential primary molecular mechanisms by which cocoa flavanols appear to
prevent or ameliorate metabolic syndrome. It is critical to clearly define the primary molecular
mechanism of action and differentiate it from downstream effects. The primary molecular
mechanism of action is the initial biological effect caused directly by the bioactive compound of
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interest. In other words, the primary molecular mechanism of action is the most “upstream”
activity induced by the compound of interest that results in the observed effects. The primary
molecular mechanism of action may then have numerous downstream consequences in various
pathways. As discussed below, most research on cocoa flavanols and other dietary bioactive
compounds in animals or humans (including studies from our lab [17,91]) has been primarily
“descriptive” in nature: a compound or food is administered, and biomarkers or outcomes are
observed. These descriptive studies demonstrate the effects of the intervention and suggest, but
do not definitively identify, primary molecular mechanisms of action by which these effects are
achieved [92]. Such studies are extremely valuable for hypothesis generation regarding the
primary molecular mechanism of action. However, mechanism-oriented research (beyond
measuring biomarkers of disease) is needed to isolate and identify the primary molecular
mechanisms of action [93–97]. One additional limitation of descriptive studies is that the
relationship between observed effects typically remains unclear. Dietary interventions may result
in modulation of several pathways or systems that all likely contribute to improvements to
glucose homeostasis. However, the order in which these improvements occur, the importance of
each observed effect in the overall improvement in glucose homeostasis and the degree to which
pathways influence one another are often not clear in descriptive studies. To elucidate primary
molecular mechanisms, studies that isolate and probe specific molecular interactions and
biological pathways (such as knockout or “knock-in” mouse models, use of receptor
agonists/antagonists, use of pathway inhibitors in cell assays, gene silencing by siRNA, etc.) are
needed.
Caution should be used when interpreting descriptive biomarker studies in search of primary
mechanism, as many different primary molecular mechanisms can have similar effects, and each
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unique primary molecular mechanism can have pleiotropic effects. Numerous studies have
demonstrated the positive effects of cocoa and cocoa flavanols, including improved glucose
homeostasis, body composition and others. However, the key initial events in the cascades of
biological processes regulating these outcomes remain to be identified. Several possibilities
include inhibition of digestive enzymes, inhibition of glucose transporters, reduced metabolic
endotoxemia and stimulation of the incretin response. In all probability, flavanols act through
various mechanisms simultaneously. The most well-studied and promising potential mechanisms
and their implications will be reviewed here.

4.1. Carbohydrate digestion

Perhaps the most direct mechanisms by which flavanols may improve glucose homeostasis is by
slowing carbohydrate digestion and absorption in the gut, as explained below.
4.1.1. Glucose homeostasis
One component of metabolic syndrome is derangement of glucose homeostasis, resulting in
hyperglycemia and glucose intolerance. Glucose levels are primarily controlled by the hormones
insulin and glucagon. These two hormones are under tight regulation in order to maintain blood
glucose levels between 4 and 7 mM in normal individuals (glucose homeostasis) [98,99]. Failure
to maintain glucose homeostasis can lead to a wide variety of conditions, including adiposity,
dyslipidemia, vascular damage, vision loss, kidney disease, neuropathy, atherosclerosis and
myocardial infarction [100,101]. When the insulin signaling pathway is impaired, as for example
due to chronic inflammation [1], a cyclical effect occurs where blood glucose levels become
elevated and β-cells are constantly stimulated. This causes β-cells to deteriorate and lose their
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ability to produce insulin, leading to prediabetes, T2DM and then frank diabetes with β-cell
failure. Inadequate insulin secretion can then lead to hyperglycemia and ketoacidosis.
4.1.2. Inhibition of digestive enzymes
Cocoa can slow the rate and extent of macronutrient digestion by noncovalently binding to and
antagonizing digestive enzymes. The complex ring structure with abundant hydroxyl groups
allows cocoa to bind to proteins, particularly digestive enzymes. Cocoa flavanols interact with
digestive enzymes by a variety of primary inhibition mechanisms [102].
Cocoa may inhibit α-amylase [36], an enzyme that breaks down starch into glucose oligomers.
There is evidence to suggest that polyphenols bind to this enzyme, reducing its activity [103].
Yilmazer-Musa et al.[103] found that grape seed extract (GSE) (including catechin, epicatechin
and PCs) with 86% total phenolics by weight was just as efficient as the drug acarbose at
inhibiting α-amylase. Acarbose, the positive control, had a median inhibitory concentration
(IC50) of 6.9 μg/ml compared to GSE with an IC50 of 8.7 μg/ml. On the other hand, white tea,
which contains predominantly monomeric flavanols and only 34% total phenolics by weight, had
an IC50 of 378 μg/ml. While total flavanol concentration plays a role in the observed IC50
values, it also appears that the more complex the structure, the greater its ability to inhibit
digestive enzymes. Thus, flavanols may reduce digestion of starches, thereby lowering glucose
absorption via inhibiting this enzyme in the diabetic population. Interestingly, α-amylase
expression is higher in individuals with T2DM than healthy individuals [46,104].
Glucosidase inhibitors are well studied and commercially available, but unwanted side effects
such as diarrhea, gas and cramping have been reported for these drugs [103,105]. Acarbose is
one such synthetic glucosidase inhibitor. Acarbose has reportedly been effective in reducing
weight gain and comorbidities related to metabolic syndrome, such as diabetes and
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cardiovascular disease [46]. Flavanols may also inhibit α-glucosidase, which cleaves small
oligosaccharides at the 1,4 linked alpha glucose residues, resulting in monomeric sugars that are
ready for absorption. This is another key enzyme involved in carbohydrate digestion. When these
enzymes are inhibited, the breakdown of carbohydrates is slowed, resulting in an attenuated
elevation of blood glucose after a meal [106]. Yamashita et al.[62] found that a 0.01% cocoa
liquor procyanidin extract inhibited α-glucosidase activity in vitro; however, this result was not
observed in an in vivo model using 250-mg/kg cocoa liquor PCs. In the study conducted by
Yilmazer-Musa et al.[103], acarbose also inhibited α-glucosidase, but the IC50 values were 13
times lower compared to acarbose's inhibitory effect on a-amylase. Notably, both GSE (IC50 =
1.2 μg/ml) and white tea extract (IC50 = 2.5 μg/ml) were more potent α-glucosidase inhibitors
than acarbose (IC50 = 90 μg/ml).
The structure of flavanols affects the affinity to which they can bind to these proteins. A study by
Barrett et al.[106] compared flavanols from grape, cranberry, pomegranate and cocoa to
determine how well each can inhibit α-amylase. It should be noted that the cocoa used in this
study primarily consisted of monomers and dimers, a composition that may not be reflective of
most cocoa powders. It was found that all compounds had an effect, but cocoa flavanols
(containing the smallest mean degree of polymerization used in the experiment) had the least
inhibitory effect on either enzyme. More complex polyphenols, such as ones found in cranberries
and pomegranates, were more successful at inhibiting the breakdown of carbohydrates [106].
Andujar and Gu state that the greater the degree of polymerization, the more potently the
polyphenol can inhibit digestive enzymes [16,36]. In addition, a study conducted by Gu et al.[36]
found that cocoa potently inhibits pancreatic amylase, pancreatic lipase and phospholipase A2.
This group also examined the effects of processing methods on inhibitory capability. They found
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that the least processed cocoa, termed lavado (an unfermented cocoa which has the greatest
concentration and largest cocoa PCs), had the strongest inhibitory effect on these pancreatic
enzymes. Inhibition of lipases will be reviewed in Section 4.6.
It has been established that cocoa flavanols can inhibit digestive enzymes, but the extent to
which this inhibition affects postprandial glucose excursions is unclear. It is also unclear if these
effects are observable in vivo. Reducing rapid increases in blood glucose after a meal is
important for patients with metabolic disorders, since it helps them maintain glucose
homeostasis. Cocoa flavanols may be as effective at inhibiting digestive enzymes as some
pharmaceuticals and therefore deserve further consideration.
4.1.3. Inhibition of glucose transporters
Cocoa polyphenols not only inhibit certain digestive enzymes, but they may also inhibit glucose
transporters. Similar to digestive enzyme inhibition, the primary molecular mechanism of action
may be nonspecific flavanol–protein interactions or competitive inhibition at the transport active
site. Inhibiting glucose transporters in the intestine could attenuate glucose excursion after a
meal. Intestinal transporters that may be inhibited include glucose transporter 2 (GLUT2) and
sodium/glucose cotransporter 1 (SGLT1) [107,108].
GLUT2 is found on both the apical and basolateral surfaces of enterocytes. GLUT2 vesicles
store the transporters within the cell and fuse with the cell membrane and facilitate transport of
glucose (similar to insulin-stimulated GLUT4) upon increased glucose load. In diabetic patients,
the control of this vesicle is lost, and increased amounts of GLUT2 transporters are always found
on the cell surface, contributing to elevated blood glucose levels. Kwon et al.[107] found that in
vitro GLUT2-mediated glucose transport was inhibited by quercetin (IC50 = 12.7 μM), but not
by epicatechin (no inhibition) or catechins (no inhibition). Further studies examining the effects
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of PCs with varying degrees of polymerization are necessary to understand whether or not
inhibition of transporters occurs in response to cocoa consumption.
SGLT1 is a Na+/glucose cotransporter, which permanently resides on the apical membrane of
intestinal epithelial cells. T2DM patients exhibit increased expression of SGLT1 compared to
healthy individuals, leading to decreased glucose control [46]. Monomeric (+)-catechin (0.5 mM)
inhibited SGLT1 in a competitive mechanism in an in vitro study using Xenopus oocytes [108].
Polyphenols found in tea [(−)-epicatechin gallate and (−)-epigallocatechin gallate] also inhibited
expression of SGLT1. The extent to which cocoa flavanols with large degrees of polymerization
can inhibit this transporter is unknown.
Flavanol metabolites that reach circulation may exert an inhibitory effect on glucose transporters
in peripheral tissues. However, the concentration of metabolites in circulation is relatively low (<
3–5 μM) and is fleeting [37,43–45,107]. Therefore, given the low bioavailability of cocoa
flavanols and short half-lives of flavanol metabolites, inhibition of glucose transporters is likely a
mechanism occurring exclusively in the gut. Again, this mechanism would be helpful for patients
with metabolic disorders because it may reduce rapid glucose excursions after a meal, therefore
promoting glucose homeostasis.
4.2. Hormonal response to meals
Cocoa flavanols also appear to modulate the secretion and activities of hormones critical for
maintenance of glucose homeostasis, as explained below.
4.2.1. Stimulating the incretin response
The incretin response may be a key mechanism enhanced by cocoa. Incretins (GLP-1, GIP) are
secreted from enteroendocrine cells after a meal. One of the roles of these hormones is to
stimulate insulin secretion for glucose disposal [109]. Incretin hormones have other effects on
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the pancreas, including increasing somatostatin secretion, decreasing glucagon secretion and
stimulating β-cell growth and neogenesis. Incretin hormones are not limited to stimulating the
pancreas; incretin receptors are found in many tissues throughout the body, including the brain,
liver, adipose and skeletal muscle. Other incretin functions include suppressing appetite,
delaying gastric emptying and increasing glycogen synthesis [110,111]. The incretin response is
impaired in noninsulin T2DM, possibly due to a lack of incretin secretion [110,112]. The incretin
response is greatly reduced when a glucose load is administered intraperitoneally compared to an
oral glucose load [113]. This suggests that the gut is an important location for interventions
targeting incretin levels and, therefore, an interesting potential target for cocoa flavanols with
poor bioavailability. It is possible that cocoa may enhance the incretin response by either
stimulating incretin release or extending the half-life of incretin hormones.
4.2.2. Incretin hormones
The incretin hormone glucagon-like peptide 1 (GLP-1) is released from epithelial endocrine Lcells found in the distal small intestine and colon. In response to either glucose or a mixed meal,
proglucagon is cleaved and GLP-1 is released into the circulation [109]. The half-life of GLP-1
is about 2 min. GLP-1 exerts biological actions via its receptors, which are found on islet α- and
β-cells in the pancreas, in the brain and on vagal afferents [110,114]. GLP-1 receptor agonists
have been developed (i.e., Liraglutide, Novo Nordisk) and promote weight loss by suppressing
hunger, reducing the duration of eating and delaying gastric emptying [114,115].
Gonzalez-Albuin et al.[116,117] showed an increase in GLP-1 concentration in healthy rats fed
an oral glucose load (2 g/kg bw) 40 min after oral gavage of grape seed procyanidin extract (1
g/kg bw) compared to control. The increased concentration was not significantly different from
the positive control treatment, 1-mg/kg bw of Vildagliptin (a DDP-4 inhibitor). Yamashita et al.
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[64] also demonstrated increased GLP-1 secretion in mice 60 min after oral gavage of 10-μg/kg
bw Cinnamtannin A2, a tetrameric cocoa procyanidin. This study was novel because it was
performed in the absence of any macronutrients. Not only did it increase GLP-1 secretion, but
insulin secretion and insulin action [measured by phosphorylation of insulin receptor substrate 1
(IRS-1) and insulin receptor (IRβ)] was increased as well [64]. However, the impact of cocoa
flavanols on incretin response in the presence of glucose is not yet known.
Gastric inhibitory peptide (also referred to as glucose-dependent insulinotropic polypeptide)
(GIP) is secreted from K cells in the proximal small intestine. The release of GIP is stimulated by
the presence of nutrients, primarily fats, in the small intestine [118]. The in vivo half-life of GIP
is approximately 5–7 min. When studying this peptide, it is important to distinguish between the
cleaved, noninsulinotropic metabolite [GIP (3–42)] versus the active hormone [GIP (1–42)]
[118]. Gonzalez-Abuin et al. [117] found that GIP concentration was significantly reduced after
a gavage of grapeseed procyanidin extract (1 g/kg bw) prior to an oral glucose load (2 g/kg bw).
This response was similar to that of the positive control, Vildagliptin. However, clinical studies
using solely pharmaceuticals (i.e. sitagliptin) find that GIP concentration and area under the
curve typically increases in healthy, nondiabetic males [119]. It is unclear why GLP-1 and GIP
seem to respond differently in response to grape seed PCs. This is an area that warrants
additional investigation, as research on flavanols has focused on GLP-1.
The primary molecular mechanism by which cocoa flavanols stimulate GLP-1 and GIP secretion
likely occurs in the secretory cells but remains unknown. It seems likely that consumption of
cocoa polyphenols stimulates the release of GLP-1, but the effects of cocoa on GIP are less
understood. It would be interesting to utilize a GLP-1 receptor knock-out model to see if cocoa
can stimulate an incretin response via GIP. Further, a double incretin receptor knock-out
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(DIRKO) model could be used to assess if an incretin response is an important mechanism
utilized by cocoa to reduce glucose excursion in an acute fashion. Stimulating an incretin
response is beneficial for patients with metabolic disorders because it assists in glucose disposal,
slows gastric emptying and reduces appetite.
4.2.3. DPP-4
Dipeptidyl peptidase IV (DPP-4) cleaves the penultimate proline or alanine residue in proteins
[120,121]. It is a transmembrane glycoprotein [122] found in nearly all human tissues and fluids
[120]. Two DPP-4 targets are GLP-1 and GIP [109,118,121]. These hormones are cleaved, and
therefore inactivated, by DPP-4 almost immediately after they are secreted from their respective
endocrine cells; consequently, the incretin hormones have short half-lives. DPP-4 levels in
patients with Type 2 diabetes, impaired glucose tolerance and/or obesity are not different than
normal controls [123,124]. DPP-4 inhibitors have been considered potential treatments for
T2DM because extending the active lifespan of these hormones could prolong the beneficial
effects that incretin hormones have on glucose control [120]. Indeed, DPP-4 inhibition has been
shown to improve glycemic outcomes in diabetic models and delay the onset of diabetes in
Zucker diabetic fatty rats [125]. DPP-4 inhibitor drugs (commonly named gliptins) mimic many
of the same actions as GLP-1 receptor agonists (stimulating insulin secretion, inhibiting
glucagon secretion, etc.) but they do not exhibit the same improvements in weight loss [110].
This is likely because the resulting increase in incretin hormones is much less compared to
activating the GLP-1 receptor directly [110]. Gliptins are currently employed as a second-line
therapy for T2DM poorly controlled by metformin alone [126–128].
It appears that inhibition of DPP-4 may be another primary molecular mechanism of action of
cocoa flavanols. Gonzalez-Albuin et al. [120] examined the effects of grape seed procyandin
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extract on DPP-4 using several methods. First, they determined that the extract is able to achieve
70% inhibition of commercial DPP-4 at the highest dose reported, 200 mg/L. Next, using
cultured Caco-2 cell epithelial monolayers, they found that 100 mg/L of grape seed extract
incubated for 3 days resulted in 20% inhibition of DPP-4 (shorter incubation periods did not
show significant changes in inhibition). This was associated with a significant reduction in DPP4 gene expression, as well. The same group examined the effects of grape seed extract on DPP-4
in in vivo models [116,117]. They found that an acute grape seed extract (1 g/kg bw) inhibits
intestinal DPP-4 activity [117].
Ultimately, it appears that while plasma DPP-4 inhibition is possible, it is likely not the main
mechanism that would result in improved glucose homeostasis [120]; gut DPP-4 inhibition is a
more plausible mechanism. DPP-4 inhibition has not been studied using cocoa extract or cocoa
powder and remains an area in need of further investigation.
4.3. Metabolic endotoxemia and inflammation
Endotoxin, or lipopolysaccharide (LPS), is derived from the outer membrane of Gram-negative
(−) bacteria. If the bacteria lyse, LPS can separate from the membrane and, if gut barrier function
is poor, the LPS can enter the circulation via paracellular diffusion and activate proinflammatory
pathways through molecular pattern recognition receptors in systemic circulation and in tissues.
Several factors appear to modulate the concentration of LPS in circulation, including the gut
microbial environment, high-fat diet and intestinal permeability [129]. Chronic, low-grade,
inflammation may contribute to the pathogenesis of obesity and metabolic syndrome. Circulating
endotoxin binds to toll-like receptor 4 (TLR4), a molecular pattern recognition receptor, and
initiates an inflammatory response [129]. This chronic, endotoxin-derived inflammation can
disrupt energy homeostasis and insulin signaling, leading to elevated blood glucose levels. If the
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bacteria lyse, LPS can separate from the membrane, and if gut barrier function is poor, the LPS
can enter the circulation via paracellular diffusion.
Recent evidence has suggested that cocoa flavanols can aid in the attenuation of this metabolic
endotoxemia [17,63]; however, the underlying mechanisms are less explored. These changes are
primarily attributed to the chronic consumption of cocoa. Possible intermediate mechanisms
responsible for this effect of cocoa are modulation of the gut microbiome composition and
function, improvements of the gut barrier function and improved insulin signaling.
4.3.1. Gut microbiota
Recently, the gut microbiome has become a very popular field of research. While once
considered a “black box,” the commensal microbial communities of the human gastrointestinal
tract are now known to be diverse and complex and to have significant impacts on human health.
It is believed that one's diet plays a large role in the development and maintenance of the
microbial community [129,130]. Further, links have been drawn between the composition of
one's microbiome and their likelihood to present with obesity or metabolic disease [130]. Certain
species are associated with harvesting nutrients and producing short-chain fatty acids, improving
the mucosa in the colon and improving gut barrier function, among many other outcomes
[131,132]. It is possible that cocoa may modulate levels and activities of certain species in the
gut microbiome, although the primary mechanisms of action by which this is achieved remain
poorly understood. Mechanistic studies are needed to understand the molecular interactions
between flavanols and commensal bacteria, both on an individual cell and community level.
A large proportion of cocoa flavanols proceed to the colon where they interact with the gut
microbiota. As discussed previously, the gut microbiota metabolize polyphenols. However,
polyphenols also modulate the gut microbiome and exert prebiotic effects. A prebiotic is defined
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as a “non-digestible food ingredient that beneficially affects the host by selectively stimulating
the growth and/or activity of one or a limited number of bacteria in the colon, and thus improves
host health” [133]. While prebiotics are commonly thought to be indigestible carbohydrates that
are fermented by gut microbiota, flavanols can also fulfill this definition. Cocoa flavanols have
shown prebiotic activity in vitro[47], in rodents [76] and in humans [134].
Tzounis et al. [47] found that incubation of (+)-catechin with fecal samples from healthy
volunteers significantly increased the growth of Clostridium coccoides-Eubacterium rectale
group, Bifidobacterium spp. and Escherichia coli, as well as a significant inhibitory effect on the
growth of the Clostridium histolyticum group. A rodent study showed decreases in Bacteroides,
Staphylococcus and Clostridium genera after a 6-week cocoa treatment (100-g cocoa/kg chow)
compared to a reference group; this study utilized healthy animals and a normal chow diet [76].
It is important to note that the dietary fiber in cocoa could potentially elicit many of these
observed benefits, and this study's control group did not have matched soluble fiber content.
Cocoa flavanols were also found to modulate human gut microbiota. After a 4-week cocoa
treatment (494-mg flavanols/day), healthy volunteers had an increase in Bifidobacterium and
Lactobacillus, and a decrease in Clostrum compared to a low flavanol treatment (29 mg
flavanols/day) group [134]. Both treatments had equal amounts of dietary fiber.
It is evident that cocoa can exert prebiotic effects in both animals and humans and improve gut
barrier function. Both of these properties would be beneficial for patients with metabolic
disorders. However, more research is necessary to understand if cocoa can exert prebiotic effects
in an unhealthy or at-risk population and to what degree the naturally occurring fiber found in
cocoa powder affects these results.
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4.3.2. Tight junction proteins
The purpose of tight junction proteins is to ensure the integrity of epithelial tissues and act as a
barrier to limit paracellular diffusion of water, ions and other molecules. Occludin, claudin and
junction adhesion molecules (JAM) are important proteins found in tight junctions between
epithelial cells [135]. The transmembrane proteins occludin and claudin attach to actin filaments
within the cell via intracellular plaque proteins, such as zonula occludens (ZO) [136].
Gut barrier function is important for human health. A high-fat diet [129], alcohol [137] and
exercise [138] can increase gut permeability. Certain diseases such as Crohn's disease,
inflammatory bowel disease and Celiac's disease are associated with compromised integrity of
the gut barrier [139]. In the perspective of metabolic syndrome and metabolic endotoxemia, a
leaky gut allows endotoxin to enter the circulation via paracellular diffusion. Systemic endotoxin
causes an inflammatory response that can disrupt insulin signaling and contribute to
atherosclerosis and obesity [140]. Therefore, improving gut barrier function is an important
target for preventing and/or resolving metabolic endotoxemia.
There has been evidence that the gut microbiome can affect gut barrier integrity [141]. The
mucus layer in the GI tract is important for gut health [142], and certain bacterial species, such as
Akkermansia, reside in this layer [143]. Increased mucus production by goblet cells is a prime
environment for mucus-eating bacterium, such as Akkermansia, which has been shown to protect
against metabolic syndrome [131]. Everard et al. [143] showed that Akkermansia is beneficial to
gut barrier function and normalizes metabolic endotoxemia. This species also improved glucose
tolerance and decreased hepatic glucose production in mice with diet-induced obesity [143].
Interestingly, Akkermansia is a Gram (−) bacterium.
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It is unclear if cocoa flavanols can increase Akkermansia populations, but flavanols have been
shown to improve gut barrier function [91,144]. While the mechanism by which this occurs
remains unknown, this protective effect against gut permeability and therefore inflammation
could be the mechanism for health-promoting effects of cocoa flavanols. This is a very intriguing
research area that should be further explored.
There has been limited evidence to suggest that flavanol consumption has been correlated with
improvements in tight junction protein expression and gut permeability. Goodrich et al. [91]
found that 0.1% GSE in drinking water (100 mg/kg/day) increased occludin expression in the
proximal colon in healthy rats compared to the control group. Another group found that GSE in a
standard chow diet (250 mg/kg/day) increased ZO-1 and occludin expression and decreased
intestinal permeability in the small intestine in healthy rats [144].
The primary molecular mechanisms behind the increased expression of tight junction proteins
are unclear, but it may be related to prebiotic-induced changes in gut microbiota. In addition,
flavanols may interact directly with the epithelium to induce these changes. Future research is
needed to determine if cocoa can protect against derangements in gut barrier function and
inflammation caused by a high-fat diet and if these changes are associated with bacterial species
such as Akkermansia.
4.3.3. Endotoxin-derived inflammation
LPS is the primary ligand for TLR4, which is found on the cell surface of immune cells, skeletal
muscle and many other tissues [145]. LPS binding to TLR4 initiates an inflammatory cascade
that leads to nuclear translocation of nuclear factor kappa B (NF-κB), resulting in production of
inflammatory cytokines [145]. Poor gut barrier function will lead to elevated plasma endotoxin
levels and metabolic disease [129]. Endotoxin-induced inflammation has been shown to disrupt
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energy homeostasis associated with metabolic syndrome [146]. Inflammation can hinder the
normal processes of many tissues, including skeletal muscle, liver, adipose, brain, pancreas and
the endothelium of arteries. Inflammation can also disrupt insulin and leptin signaling; both of
these hormones are involved with perceptions of satiety and fuel handling [147].
Several studies have explored the effects of cocoa on inflammation and its contribution to
diseases [73,75,86,148]. There are also studies investigating the effects of cocoa on metabolic
endotoxemia [17,75]. A study conducted by Gu et al.[63] examined the effects of an 18-week
cocoa treatment (8% w/w cocoa powder in a high-fat diet) in male mice on cytokine and
endotoxin levels. It was found that the cocoa treatment was effective in reducing plasma LPS,
TNFα and IL-6 compared to the control high-fat diet group. This study also showed that the
cocoa treatment improved gut barrier function, resulting in 40.8% lower plasma endotoxin levels
compared to the high-fat diet group. Dorenkott et al. [17] also saw reductions in serum endotoxin
levels, along with improvements in glycemic outcomes, in a similar study using a lower dose
(25-mg/kg bw of cocoa extract monomeric and oligomeric fractions) for 12 weeks. Both studies
utilized a C57Bl/6 mouse model on a high-fat diet.
Overall, cocoa and other flavanols have the potential to improve gut barrier function, which may,
in turn, alleviate metabolic endotoxemia. Further research is needed to confirm these results, and
a clinical study is warranted. It is unknown if reduced endotoxemia is due solely to alterations to
gut microbiota and barrier function, or if flavanols can directly bind and inactivate LPS in the gut
or blood, or modulate LPS-TLR4 binding and downstream signaling at the levels of skeletal
muscle cells.
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4.4. β-cells
Deterioration of functional β-cell mass is observed during T2DM and metabolic syndrome
disease progression. Functional β-cell mass is defined as the β-cell insulin secretion rate, and the
total β-cell mass is a factor of cellular proliferation and cellular death [149]. Decreased
functional β-cell mass critically impinges on the ability to maintain normoglycemia. There are
various studies that suggest that cocoa polyphenols may protect β-cells against death-inducing
damaging factors, enhance glucose stimulated insulin secretion and induce β-cell replication. The
primary molecular interactions by which flavanols induce improved β-cell function, proliferation
and survival remain unknown and, therefore, warrant investigation.
T2DM and other metabolic diseases are associated with chronic, low-grade inflammation and
excess reactive oxygen species, which can damage β-cells, thereby further exacerbating
metabolic instability. Individuals with metabolic disorders can also present with a decrease in
antioxidant potential (i.e., glutathione levels), so a dietary antioxidant may be beneficial for the
health of these patients. Cocoa polyphenols have antioxidant properties and may help protect βcells from oxidative damage. Further, Martín et al.[150] showed that cocoa flavanols protected
against oxidative stress in INS-1 cells, a rat insulin-secreting cell line. Similarly, Youl et al.
[151] demonstrated that quercetin (which has also been found in cocoa [152] although not a
flavanol) is able to protect INS-1 cells from oxidative damage, supporting the findings that cocoa
flavanols protect against oxidative stress. Most recently, in a rodent model using Zucker diabetic
fatty rats, a 9-week treatment with cocoa-enriched diet (10% (w/w) cocoa powder) prevented βcell apoptosis by reducing oxidative stress [71]. These data are supported by studies showing that
quercetin prevents streptozotocin-induced oxidative stress and damage [153,154]. These data
strongly demonstrate that in animal models of β-cell destruction, there is appreciable protection
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given to the β-cell mass from flavanol compounds, in particular from cocoa. However, it is
unclear if the cocoa flavanols act as reducing agents in the gut (possibly on acrylamide), in the
circulation or in the pancreas directly. Further studies are needed to identify the exact location
that these antioxidant effects are taking place in an in vivo model and at doses more comparable
to human intake.
Cocoa may exert protective effects on β-cells by inhibiting lipid accumulation in the cells. While
peripheral insulin resistance is common during obesity and aging in mice and people, its
progression to T2DM is largely due to insulin secretory dysfunction and significant apoptosis of
functional β-cells. Accumulating evidence suggests that chronic hyperlipidemia (lipotoxicity)
causes β-cell apoptosis and impairs its function, thereby contributing to the pathogenesis of
T2DM [155]. In a study with cafeteria-fed rats, treatment with grape seed procyanidin extract for
30 days significantly reduced triglyceride levels in the pancreas, resulting in improved insulin
secretion [156]. Further studies are needed to examine the impacts of cocoa flavanols with
differing degrees of PCs on β-cell health and function.
Cocoa flavanols, in particular epicatechins, have been shown to enhance glucose-stimulated
insulin secretion [88]. Early studies demonstrated that epicatechins are sufficient to increase
insulin secretion from rat islets [157]. More recent studies using ob/ob rats fed cocoa extracts
demonstrated that in addition to decreasing oxidative stress, the treatment enhanced insulin
secretion [158]. Using quercetin treatment of INS-1 cells, it was shown that the flavonolmediated potentiation of insulin secretion was dependent on MEK-regulated phosphorylation of
Erk1/2 [151]. These data clearly demonstrated that the flavonols, and similar compounds such as
flavanols, were able to protect against oxidative stress and enhance insulin secretion. Preliminary
studies suggest that similar effects are seen in human populations; consumption of high
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polyphenol dark chocolate for a 15-day period increased the 2-h corrected insulin response,
which suggests improved β-cell function in these individuals [80]. Taken together, these data
suggest that cocoa flavanols have the capacity to enhance glucose-stimulated insulin secretion
and thereby enhance functional β-cell mass.
Finally, a number of studies have demonstrated that cocoa-derived compounds can induce β-cell
proliferation. β-cell proliferation is a highly regulated process, and in the majority of individuals,
less than 1% of β-cells can be measured replicating after adolescence [159]. Therefore,
compounds and factors that enhance proliferation would have a direct therapeutic effect with
patients suffering from T2DM or metabolic syndrome. Early studies demonstrated enhanced
DNA replication and regeneration of β-cells when rats were treated with epicatechins [160–162].
Studies using quercetin (a flavonol, also found in cocoa) in the STZ-treated rat diabetes model
demonstrated maintenance of β-cell mass, which could indicate decreased cell death or enhanced
proliferation [153,154]. These data were validated in the NOD (nonobese diabetic) T1DM model
where epicatechin treatment increased β-cell mass [163]. Finally, rats fed a cocoa-rich diet had
increased small islet size and maintenance of total islet mass, suggesting induction of β-cell
proliferation [71]. Taken together, these data demonstrate that cocoa flavanols have beneficial
effects on β-cells: enhanced survival, insulin secretion and proliferation. The molecular
mechanisms by which these effects are induced are yet to be elucidated.
4.5. Insulin signaling
It is increasingly recognized that chronic inflammation is associated with defective insulin
signaling and insulin resistance. It has been shown that proinflammatory molecules inhibit the
insulin-signaling pathway. For example, tumor necrosis factor-alpha (TNF-α) can induce the
phosphorylation of the serine residues on IRS-1, which subsequently inhibits tyrosine auto-
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phosphorylation of the insulin receptor [164], thereby impairing glucose disposal. Chronic
hyperglycemia is toxic to pancreatic β-cells, causing impairments in insulin secretion and cell
apoptosis, therefore further exacerbating elevated glucose levels.
Cordero-Herrera et al. [165,166] studied the effects of epicatechin and cocoa extract at
physiologically relevant doses on insulin-signaling mechanisms in HepG2 cells. Both treatments
successfully enhanced the activities of IR, IRS-1, IRS-2, PI3K/AKT pathway and AMPK.
However, it is unclear if the Phase-II and/or colonic metabolites would produce the same effects
as the native polyphenols. Future studies may want to examine these outcomes with conjugated
metabolites of epicatechin and other flavanols, since the metabolites would be most prevalent in
circulation compared to native flavanols.
Yamashita et al. [62] showed that cocoa liquor extract provoked the translocation of GLUT4 to
the plasma membrane in absence of insulin in L6 myotubes. This is an interesting finding for
several reasons. Individuals with T2DM have a blunted GLUT4 translocation in response to
insulin, despite the fact that they typically have normal amounts of GLUT4 expression in skeletal
muscle [19,23,167]. If cocoa can promote the translocation of GLUT4, glucose disposal will be
enhanced and blood glucose levels will normalize. Since this is an insulin-independent
mechanism, this is especially useful for diabetic patients who may have deficits in insulin
production. Future studies are warranted to see if these outcomes are reproducible in vivo.
Cocoa polyphenol extract was shown to inhibit insulin receptor kinase by direct binding,
resulting in reduced lipid accumulation and differentiation in preadipocytes in vitro[168]. This is
thought to be one mechanism by which cocoa flavanols may inhibit the onset of obesity.
In conclusion, cocoa may modulate insulin signaling in several ways. First, a heightened incretin
response, discussed in Section 4.2.2, will promote insulin secretion. Second, if cocoa can
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improve gut barrier function, it will lend to a reduction in LPS and chronic inflammation,
resulting in improved insulin signaling. Third, cocoa flavanols reduce insulin resistance by both
insulin-dependent and insulin-independent mechanisms (including activation of the insulinsignaling cascade in the absence of insulin). Glucose intolerance and insulin resistance are
characteristic of metabolic syndrome. Dietary components aiding in either insulin secretion or
insulin action would prove beneficial for patients with metabolic syndrome. However, the
cellular mechanisms by which cocoa flavanols achieve these effects in glucose-disposing tissues
remain unknown. Further research with pathway inhibitors, overexpression and gene-silencing
experiments is needed to move beyond identification of up-regulated/stimulated pathways and
pinpoint the mechanistic targets that produce those effects (such as AMPK signaling, CAMK
signaling, PI3K/Akt signaling, etc.). This, in turn, will enable therapeutic targeting of those
primary mechanisms.
4.6. Other potential mechanisms
The mechanisms addressed in this review are only a portion of the proposed mechanisms that are
reported in the literature. Other mechanisms by which cocoa may affect health outcomes are
important to acknowledge in order to fully understand the potential effects that cocoa flavanols
may have on glucose homeostasis.
This includes an antioxidant potential of cocoa flavanols that can be very beneficial to
cardiovascular health and has been extensively studied and reviewed elsewhere [169]. Cocoa can
impact nitric oxide production, endothelial function and, ultimately, atherosclerosis.
Cardiovascular health is an important facet of metabolic syndrome and must not be overlooked
when developing drugs or designing studies to alleviate or assess this metabolic disorder.
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Oxidative stress is present in obesity and metabolic syndrome. Reactive oxygen species can
accumulate in metabolically active tissues and cause lipid peroxidation, damage β-cells,
modulate the gut microbiota and hinder cardiovascular function, insulin signaling and
mitochondrial function. Flavanols may protect against the effects of oxidative stress [28].
Gu et al.[75] suggests that inflammation can be reduced by cocoa flavanols via reducing lipid
absorption. Along with the digestive enzymes already discussed, flavanols also inhibit digestive
lipases, which results in increased lipid content in fecal matter. Further, this will reduce
macrophage infiltration into adipocytes, lowering inflammatory tone [75].
Dyslipidemia is an important facet of metabolic syndrome. Many studies have examined the
effects of chronic cocoa treatments on LDL cholesterol, HDL cholesterol and triglycerides
[78,79,84,156,170–173]. Cocoa may be able to beneficially modulate cholesterol and triglyceride
levels in metabolically unhealthy individuals [174]. Cocoa flavanols may improve blood glucose
control indirectly, by modulating lipid digestion and thus reducing hyperlipidemia and its
subsequent deleterious effects on glucose homeostasis. PCs are potent lipase inhibitors in
vitro[36,175]; they also reduce acute postprandial [175] and fasting plasma triglycerides [63] and
increase fecal lipid excretion [75] in animals and humans. It has been well established that cocoa
and PCs reduce blood triglycerides and lipid accumulation in viscera, liver and β-cells in animal
models [18,75,158,176,177]. Prevention of lipid accumulation by cocoa PCs may indirectly
improve glucose homeostasis by preserving metabolic flexibility and insulin sensitivity in
skeletal muscle [178,179], insulin sensitivity in liver [180,181] and β-cell viability and function
[71,150,177,182]. Clinical studies have shown that inhibition of lipid absorption and associated
hyperlipidemia and fat accumulation can improve blood glucose control and insulin sensitivity in
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humans [183–185]. Cocoa flavanols have not been evaluated for inhibition of lipid digestion and
absorption in humans.
Finally, cocoa flavanols have been associated with an increase in lipolysis, fatty acid oxidation
and energy expenditure in animal models [65,69,70,186–189]. Other suggested mechanisms
involve the endocannabinoid system [146], mitochondrial function [190], anticarcinogenic
properties [155] and modulating immune function [24].
In summary, there are many possible primary and intermediate mechanisms that are outside the
scope of this review, but they are still important to consider when evaluating the effects of cocoa
on metabolic syndrome. It is likely that cocoa and cocoa flavanols exert pleiotropic effects on
metabolism, which likely act synergistically to prevent or slow prediabetes and T2DM.
However, it remains unknown which mechanisms and pathways are affected directly by cocoa
and which are modulated indirectly as downstream effects of improvements in the primary
targets. In some cases, definitive identification of the primary molecular mechanism of action
may be unnecessary. However, when moving forward to expensive, time-consuming clinical
trials, knowledge of the most upstream targets will facilitate improved study design,
identification of appropriate biomarkers to evaluate efficacy and, perhaps most importantly,
define the biological contexts in which cocoa flavanols are likely to be effective.

5. Implications of potential mechanisms

As detailed above, cocoa flavanols appear to possess important antidiabetic activities. In some
cases, these activities are similar to current pharmaceuticals for control of diabetes and obesity
[191], such as acarbose [192,193], gliptins [126,194,195] and orlistat [183–185]. Increased
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intake of cocoa flavanols may represent a viable dietary strategy to obtain the glucose-lowering
benefits of these pharmaceuticals without the deleterious side effects (oily stool, diarrhea, gas,
bloating, etc.). However, the clinical utility of cocoa in preventing and ameliorating prediabetes
and/or T2DM by exploiting these mechanisms remains largely unknown.
5.1. Importance of understanding mechanism
Strategies that maximize the efficacy of flavanol interventions are desirable. However, as
discussed above, the primary mechanism(s) by which flavanols act in vivo remain poorly
understood. This mechanistic uncertainty limits our ability to focus on modulating specific
mechanistic targets. Furthermore, the impact of flavanols on various substates of diabetes
(prediabetes, early T2DM with hyperinsulinemia, late T2DM with β-cell exhaustion/failure, etc.)
remains poorly understood. This precludes targeting of specific substates (such as impaired
fasting glucose versus impaired glucose tolerance, which typically present exclusively of each
other in prediabetes [196–198] and primarily represent derangements of gluconeogenesis versus
insulin sensitivity, respectively) as opposed to a “shotgun” approach that does not require
mechanistic knowledge and does not finely target specific physiological conditions.
Similarly, understanding the location of activity is key for targeting. If the primary mechanism is
located in the gut, strategies to maximize gut levels and activity should enhance efficacy.
Conversely, if the primary molecular mechanism is located in peripheral tissues, strategies to
enhance flavanol bioavailability would be most likely to improve efficacy [199–201].
Furthermore, an understanding of whether native flavanols, or their microbial metabolites, are
primarily responsible for the observed benefits would be useful to design strategies to increase
native flavanol bioavailability or increase microbial metabolism of flavanols.
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Lack of definitive mechanistic data limits current flavanol intervention strategies to “shot in the
dark” approaches within a specific target dose, which may result in suboptimal efficacy and
attempted use in populations that may not benefit from cocoa interventions. Therefore,
clarification of the mechanisms involved is essential to improve clinical utility of cocoa
flavanols.
5.2. Implications of bioavailability on mechanism
Some of the proposed mechanisms suggest that cocoa flavanols may improve glucose control at
least in part by acting locally in the gut lumen. This is critical due to the fact that flavanols,
particularly the PCs (i.e., the larger flavanols), have poor systemic bioavailability [29–31,202–
205]. Reported oral bioavailability of flavanols is generally < 10% for monomeric catechins
[206,207] (when Phase-II metabolites are accounted for, bioavailability of monomers from
catechins has been reported as high as 55%), much lower for small PCs (dimers-, trimers) and
essentially 0% for larger PCs [29,39,207,208].
Poor bioavailability likely limits flavanol activities in peripheral tissues compared to the gut.
Following cocoa consumption, concentrations of major flavanols (epicatechin, procyanidin B2,
etc.) in circulation are typically 0.010–6.0 μM [37,43–45]. By comparison, consuming a 5-g
serving of cocoa powder (~ 6-mg catechin, 25-mg epicatechin and 235-mg PCs) would result in
gut concentrations of ~ 10-μM catechin, 43-μM epicatechin and 67-μM PCs (assuming
intermediate size PCs and gastrointestinal fluid volume of 2 L) [209]. Therefore, cocoa flavanols
are typically much more concentrated in the gut compared to peripheral tissues. The hypothesis
of gut activity is strengthened by an intriguing study demonstrating that orally administered
flavanols improved glucose tolerance in animals when glucose was administered orally, but not
when glucose was administered by intraperitoneal injection [120]. Despite this evidence, the gut-
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located activities (inhibition of digestive enzymes, improved barrier to endotoxin, stimulation of
GLP-1 secretion, etc.) of cocoa flavanols have not yet been rigorously tested nor targeted in vivo
for inhibition or improvement of metabolic syndrome. Mechanistic animal and human clinical
experiments are needed in order to demonstrate the ability of cocoa flavanols to act specifically
by gut-mediated mechanisms. Demonstration that cocoa flavanols act through gut mechanisms is
needed so that delivery and dosing strategies may be designed to specifically target these
mechanism(s) and optimize intervention efficacy, as well as identify behaviors and nutrition
profiles that optimize the efficacy of these digestive effects.
5.3. Implications of mechanism on dose distribution
Acute human studies demonstrate that consuming flavanols with a meal can lower postprandial
hyperglycemia [210–214]. Thus, co-consuming flavanols with meals may be a viable strategy for
improving both acute and long-term blood glucose control, as well as reducing dyslipidemia.
However, several of the proposed activities of cocoa flavanols (inhibiting carbohydrate/lipid
digestion and improving the “incretin effect”) require the presence of flavanols in the lumen of
the gut concurrent with macronutrients during digestion, similar to acarbose or orlistat. If coconsumption of flavanols with meals significantly improves acute glucose control and blood
lipid profiles, it follows that chronic flavanol co-consumption with meals should maximize their
activities compared to consumption at other times. Conversely, if acute effects require coconsumption with meals, consuming flavanols between meals may reduce their potential
benefits; cocoa flavanols cannot inhibit macronutrient digestion if the two are not present at the
required concentrations in the gut lumen simultaneously. However, it remains largely unknown
whether consuming flavanols with meals (vs. other patterns) maximizes their efficacy or if dose
distribution does not affect efficacy.
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Most animal studies [68,69,158,215], including those in our lab [17,91], administer flavanols
incorporated into the diet (thus, flavanols and macronutrients are always co-consumed). Human
interventions are not necessarily designed to recapitulate animal dosing patterns; rather,
emphasis is simply placed on translating the effective dose from animals to humans. This may
account for partial loss of efficacy during translational research. In at least four out of the
reported effective chronic flavanol clinical interventions, dosing was synchronized with meals or
distributed widely throughout the day [78–82,216,217]. Conversely, only one of the reported
ineffective interventions was synchronized with a meal [84,86,218,219]. The preliminary
evidence therefore suggests that dosing strategies may matter in terms of flavanol efficacy.
Consuming flavanols with meals, or evenly throughout the day, appears to maximize efficacy.
Variations in design make it impossible to definitively assess the impact of dosing strategy from
published studies [78–82,84,86,216–219]. However, to our knowledge, the impact of different
flavanol dosing strategies on biomarkers of metabolic syndrome has not been rigorously tested.
Studies are needed which examine the impact of dose distribution on efficacy.
5.4. Relationship between mechanism and effective dose
Animal and clinical studies alike have used drastically different doses of cocoa treatments,
including doses that are likely not translatable to humans [17,71,85,86,190,220]. Different
mechanisms likely have distinct effective doses; since the mechanisms behind the beneficial
health outcomes associated with cocoa have yet to be determined, it may be difficult to pinpoint
an ideal dose before the mechanisms are defined. However, the “more is better” concept often
used for phytochemical is inherently flawed, as many phytochemicals exhibit U-shaped dose
response curves where lower doses are more effective, likely due to lower levels of
detoxification pathway expression and different binding efficiencies for receptors and enzyme
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active sites and others [221,222] (this is known as “hormesis”) [223,224]. Higher doses can
result in reduced efficacy compared to lower doses, no effect or even toxicity. The use of high
doses can therefore mask potential efficacy of mechanisms that may be relevant to humans at
translatable doses. Furthermore, nontranslatable doses may modulate mechanisms that are not
impacted at lower doses, thus suggesting potential mechanisms of action that are unlikely to be
modulated once translated to human dosing. Therefore, future studies should ideally be designed
to examine the effects of lower, translatable doses of cocoa flavanols.
5.5. Relationship between flavanol structure and mechanism
Cocoa flavanols exist in a broad range of polymerization states. Different flavanols likely act
through distinct mechanisms due to differences in structure as well as bioavailability. Animal
studies have generally focused on whole cocoa or chocolate [71,74–76,215,225–227], extracts
[62,66–69,228,229] and flavanol monomers (catechins) [65,190,214,230]. Little data exist on the
bioactivities of larger flavanols (PCs), partly due to difficulty of isolation, complexity of
analytical characterization and lack of commercially available standards. However, recent data
have suggested that the PCs may possess distinct (and in some cases, enhanced) activities for
improvement of glucose homeostasis compared to flavanol monomers. Gu et al.[102]
demonstrated that flavanol DP was inversely correlated to the IC50 of digestive enzyme
inhibition (larger cocoa flavanols were more effective inhibitors). Yamashita et al.[231] showed
that a fraction composed of smaller cocoa flavanols (DP ≤ 3) more effectively stimulated glucose
uptake, GLUT4 translocation and AMPK phosphorylation in skeletal muscle cells than a fraction
composed of larger PCs (DP ≥ 4). However, in the same study, the larger flavanols were more
effective α-glucosidase inhibitors than the smaller flavanols. Yamashita et al.[64] further
demonstrated that cinnamtannin A2 (a DP 4 cocoa flavanol) increased circulating GLP-1, insulin
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levels and activation of the insulin-signaling pathway ins skeletal muscle in mice, whereas cocoa
flavanols with DP 1-3 had little to no effect. Subsequently, we demonstrated that oligomeric
cocoa flavanols more effectively inhibited the onset of diet-induced obesity and glucose
intolerance compared to a crude cocoa polyphenol extract, monomeric cocoa flavanols and
polymeric cocoa flavanols [17]. This finding was intriguing, as the bioavailability of oligomeric
flavanols is lower than that of monomeric flavanols (see above). Thus, these enhanced activities
may be due to mechanisms that do not require bioavailability.
These data suggest that cocoa flavanols of different DP may possess distinct activities. As cocoa
contains a wide distribution of flavanol DPs, this emphasizes that the observed bioactivities are
likely due to a variety of compounds acting through various mechanisms synergistically.
Understanding the relationship between flavanol DP and bioactivities will facilitate an
understanding of how cocoa composition impacts potential health benefits. Despite the cost and
complexity associated with preparing or obtaining these larger flavanols, the influence of DP on
flavanol bioactivity warrants further investigation. This is another emerging area with the
potential to yield highly valuable, novel data to clarify the role of cocoa flavanols in metabolic
syndrome. Efforts to isolate, purify, characterize and make these compounds available to other
diabetes researchers will be central to this effort.

6. Conclusions

In conclusion, cocoa flavanols appear to alleviate metabolic syndrome, and specifically,
derangements in glucose homeostasis, by several intermediate mechanisms. First, cocoa may
reduce glucose excursion after a meal by inhibiting digestive enzymes, inhibiting glucose
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transporters and promoting an incretin response. These outcomes are most likely to be observed
after an acute dose of cocoa, and since these mechanisms predominantly occur in the gut, the
poor bioavailability of flavanols is not a limiting factor for these activities.
Second, chronic cocoa consumption may lead to beneficial changes in the gut microbiota,
resulting in improved gut barrier function, reduced circulating endotoxin and uninhibited insulin
signaling mechanisms. PCs are stable through gastric and intestinal transit so they will reach the
colon intact. Again, bioavailability is not a limiting factor.
Third, cocoa flavanols can act in peripheral tissues (improved β-cell function and insulin
sensitivity in skeletal muscle, etc.). These effects are limited by the poor bioavailability of many
cocoa flavanols. Demonstration of the activities of flavanol microbial metabolites may be the
missing link between oral flavanol consumption and activity in peripheral tissues.
It is likely that the potential benefits of cocoa consumption are mediated by all of these
mechanisms to some extent. However, it remains unknown which, if any, of these mechanisms
are primarily responsible for observed effects in vivo. Furthermore, the primary molecular
mechanisms by which these intermediate mechanisms occur are generally unknown. Therefore,
additional in vivo mechanistic studies are needed in order to isolate and assess individual primary
and intermediate mechanisms of action.
There are many elements of this puzzle that are still unknown. First, it is unknown what acute
effects cocoa may have on carbohydrate digestion in a population with existing prediabetes or
T2DM. So far, to our knowledge, the only acute studies (in both animal and clinical models)
have examined healthy subjects or animals. Individuals with metabolic disorders will benefit
greatly from a supplement to control glucose excursions, but it is unclear to what extent cocoa
can be helpful in this population. Second, little is known regarding the impact of cocoa on human
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subjects with differing substates along the continuum of diabetes. In addition, studies examining
the impacts of cocoa and its mechanisms of action when administered in conjunction with
common diabetes medications in subjects with T2DM (which is likely to occur in real-world
clinical settings) are needed. Third, cocoa is metabolized in the colon by the microbiota into
many metabolites and it is unknown what functions, if any, that these metabolites have on human
health. Third, it is hypothesized that Akkermansia has beneficial effects on gut barrier function,
but it is still unknown if cocoa can modulate this species, but this may be a worthwhile study to
pursue. Lastly, it is unknown what doses of cocoa (for either acute or chronic outcomes) elicit
the most beneficial outcomes related to metabolic syndrome.
Therefore, highly mechanistic clinical and animal studies are needed, in addition to the largely
descriptive studies done thus far. Based on the proposed mechanisms, acute and chronic cocoa
studies should be designed to assess mechanism. Acute studies should focus on the impact of
cocoa consumption on starch, disaccharide and triglyceride digestion (to assess the impact of
cocoa on α-amylase, α-glucosidase and lipase activity, respectively) following mixed meals as
well as individual macronutrient doses and postprandial hormone secretion (GLP-1, GIP, insulin,
etc.) following mixed meals as well as simple sugar and complex carbohydrate doses.
Chronic studies should focus on gut permeability, fasting and postprandial circulating endotoxin
levels, fasting and postprandial circulating hormone levels (GLP-1, GIP, insulin, etc.), skeletal
muscle metabolism, effects of gut microbiota/metabolites and dose synchronization with meals.
Such studies will greatly improve the depth of our understanding of the impacts of cocoa
consumption on human physiology. In order to probe the impact of cocoa flavanols on incretin
pathways (secretion, action and degradation), various techniques can be employed, including
incretin or incretin receptor knockout models, DPP-4 knockout or overexpression models,
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incretin receptor antagonists and others. To explore the impact of dose synchronization with
meals, various patterns of dosing can be employed in both animals and human subjects (single
daily flavanol dose with a meal, dose single daily dose in the fasted state, multiple daily doses
with meals, multiple daily doses in between meals, etc.). Finally, to determine the impact of gut
microbiota (and flavanol metabolites produced by gut microbiota) in mediating the effects of
flavanol consumption, studies can be performed in germ-free, gnotobiotic or antibiotic-treated
animals and compared with results of normal, fully-colonized animals. This will facilitate
identification of effects dependent upon the presence of gut microbiota.
In addition, use of advanced physiology assays in chronic human studies is needed to delineate
the precise metabolic effects of chronic cocoa exposure in study subjects. Specifically, the
insulin-augmented intravenous glucose tolerance test (IVGTT) could be performed to
simultaneously assess glucose effectiveness (ability of the body to stimulate glucose uptake and
suppress endogenous glucose production due to the presence of glucose), insulin response to
glucose and insulin sensitivity. Alternatively, the hyperglycemic glucose clamp or
hyperinsulinemic–euglycemic clamp techniques could be employed. Such studies are needed in
order to go beyond fasting glucose/insulin levels, postprandial oral glucose tolerance and the
homeostatic model assessment (HOMA) protocols commonly used [232]. In addition, skeletal
muscle biopsies followed by metabolism and energetics assays could reveal much information
regarding the impact of cocoa on substrate metabolism, metabolic flexibility and muscle function
(and improvement on deranged metabolic states observed during metabolic syndrome) [233–
240]. While these assays are more complex, burdensome to subjects and expensive, they are
needed to advance our knowledge of the mechanisms by which cocoa exerts it effects. Perhaps
most importantly, additional long-term (1 month or longer) intervention trials are needed in
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individuals with prediabetes or diabetes in order to determine the clinical utility of cocoa
flavanols for successful prevention or amelioration of these diseases.
In future studies, it is critical that all trials publish a full characterization of the cocoa utilized in
the study, due to the impact of flavanols structure on potential mechanisms of action. Clinical
studies should report the food matrix used in the treatment, and animal studies should report food
intake. Finally, utilizing acute and chronic study designs will be important to characterize the
mechanisms of action of cocoa flavanols.
Insights into the mechanisms by which cocoa flavanols act and the substates of diabetes
modulated by cocoa flavanols will refine the ability of clinicians to effectively use cocoa, in
combination with diet, exercise and medications, to effectively combat prediabetes and T2DM.
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BRIDGE BETWEEN MANUSCRIPTS
As previously discussed in manuscript one, several studies have demonstrated that cocoa
flavanols improve blood glucose levels. Pancreatic β-cells are central for the maintenance of
healthy glucose levels in the body and cocoa flavanols have been shown to positively impact βcells through enhanced survival, proliferation, and insulin secretion. However, the molecular
mechanisms underlying these results were not identified in these studies. Therefore, we
determined to construct a study that would define what molecular interactions may be
responsible for improved β-cell function and published our results as part of the following
manuscript.
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Abstract
A hallmark of type 2 diabetes (T2D) is β-cell dysfunction and the eventual loss of functional βcell mass. Therefore, mechanisms that improve or preserve β-cell function could be used to
improve the quality of life of individuals with T2D. Studies have shown that monomeric,
oligomeric and polymeric cocoa flavanols have different effects on obesity, insulin resistance
and glucose tolerance. We hypothesized that these cocoa flavanols may have beneficial effects
on β-cell function. INS-1 832/13 derived β-cells and primary rat islets cultured with a
monomeric catechin-rich cocoa flavanol fraction demonstrated enhanced glucose-stimulated
insulin secretion, while cells cultured with total cocoa extract, oligomeric or polymeric
procyanidin-rich fraction demonstrated no improvement. The increased glucose-stimulated
insulin secretion in the presence of the monomeric catechin-rich fraction corresponded with
enhanced mitochondrial respiration, suggesting improvements in β-cell fuel utilization.
Mitochondrial complex III, IV and V components are upregulated after culture with the
monomer-rich fraction, corresponding with increased cellular ATP production. The monomerrich fraction improved cellular redox state and increased glutathione concentration, which
corresponds with Nrf2 nuclear localization and expression of Nrf2 target genes including NRF-1
and GABPA, essential genes for increasing mitochondrial function. We propose a model by
which monomeric cocoa catechins improve the cellular redox state, resulting in Nrf2 nuclear
migration, and upregulation of genes critical for mitochondrial respiration, glucose-stimulated
insulin secretion and ultimately improved β-cell function. These results suggest a mechanism by
which monomeric cocoa catechins exert their effects as an effective complementary strategy to
benefit T2D patients.

Keywords: cocoa; β-cell; catechin; insulin secretion; mitochondrial respiration; Nrf2
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1. Introduction
The incidence of type 2 diabetes (T2D) is increasing at an alarming rate. There are an
estimated 415 million people worldwide that are diabetic, with current projections of 642 million
people being diabetic by 2040, with the vast majority suffering from T2D [1]. T2D is
characterized by hyperglycemia and hyperlipidemia due to muscle, adipose and liver insulin
resistance [2, 3]. In addition, studies have begun to demonstrate that decreased functional β-cell
mass is an early and essential step in T2D disease progression [4].
The primary purpose of the β-cell is to maintain normoglycemia through glucosestimulated insulin secretion. The β-cell dysfunction observed in T2D results in decreased and
poorly controlled insulin secretion and, ultimately, β-cell death [4]. Mechanisms that increase
functional β-cell mass could, therefore, be leveraged as a treatment for T2D.
Recent studies have shown that diets supplemented with cocoa or flavanols present in
cocoa have potentially beneficial effects for the T2D patient [5]. Some of these studies have
suggested that these effects may include increased cellular antioxidant abilities [6, 7]. Given the
fact that β-cells are particularly sensitive to oxidative stress, flavanol compounds found in cocoa
may have direct therapeutic applications for the control and prevention of T2D [8].
Cocoa contains a complex profile of monomeric flavanols (catechins such as epicatechin)
and their oligomeric and polymeric forms (procyanidins) (Figure 1). Using fractionation
methods, our group has begun to differentiate the effects of these distinct flavanol fractions. We
have previously shown that these fractions have different whole-body effects in regard to dietinduced T2D. These findings demonstrated that oligomeric cocoa procyanidins have the greatest
effect in preventing high fat feeding-induced weight gain while maintaining normal fasting
glucose, insulin levels, glucose tolerance and insulin sensitivity [9]. However, these are whole-
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body effects, and studies are needed to describe the effect of various cocoa flavanols fractions on
various tissues affected by T2D. We recently demonstrated differential impacts of these fractions
on insulin signaling and glucose utilization in skeletal muscle cells [10]. However, no data exist
on how these fractions may affect pancreatic β-cell function, which is critical for preventing or
ameliorating T2D.
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Figure 1 -Structures of selected representative flavanols found in cocoa. (−)-epicatechin monomer and procyanidin
oligomers/polymers comprised of (−)-epicatechin monomers linked (4β → 8).
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Previous studies suggest that cocoa flavanols protect and/or improve β-cell function. These
effects appear to include enhanced survival, insulin secretion, and proliferation. In vitro, cocoa
flavanols protect against oxidative stress in INS-1 cells and increase insulin secretion from rat
islets [11]. In Zucker diabetic fatty rats, dietary cocoa prevents β-cell apoptosis by reducing
oxidative stress, and also increases small islet size and maintenance of total islet mass,
suggesting induction of β-cell proliferation [7]. In ob/ob and normal rats, cocoa flavanol
treatment enhances insulin secretion [6]. In a non-obese Type 1 Diabetic model, application of
cocoa flavanols increases β-cell mass [12]. Additionally, cocoa flavanol treatment enhances
DNA replication and regeneration of β-cells in rats [13-15]. Finally, in humans, cocoa flavanols
enhance postprandial insulin secretion [16]. Despite these promising results, the molecular
mechanisms by which these improvements occur are yet to be elucidated.
The transcription factor Nrf2 (Nuclear Factor, Erythroid 2 Like 2, also known as
NFE2L2) controls the cellular response to oxidative stress [17]. Under normal conditions, Nrf2 is
bound in the cytosol by the Kelch-like ECH-associated protein 1 (Keap1) and targeted for
proteolytic degradation, thus suppressing Nrf2-mediated transcriptional activity [18]. Under
oxidative stress conditions, however, Keap1 cysteine residues are oxidized, resulting in Nrf2
release and nuclear translocation [19]. Upon nuclear translocation, Nrf2 induces expression of
genes whose promoters contain antioxidant response elements (ARE) [20]. Many of these Nrf2
regulated genes are involved in processes to quench free radicals and ultimately upregulate the
cell’s ability to decrease oxidative stress. While direct Nrf2 targets involved in antioxidant
response have been defined for some time, recent studies have demonstrated that Nrf2 also
enhances expression of genes that regulate mitochondrial function [21].
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The transcription factors NRF-1 (Nuclear Respiratory Factor 1) and GABPA (GA
Binding Protein Transcription Factor Alpha Subunit, also known as Nuclear Respiratory Factor
2) are essential for mitochondrial function and biogenesis [22]. These transcription factors
directly control expression of genes involved in the electron transport chain, as well as enhance
expression of genes such as TFAM that drive mitochondrial production [22, 23]. Cellular
response to events that require increased mitochondrial function are dependent on the function of
these transcription factors. Given that glucose-stimulated insulin secretion is intimately
connected to mitochondrial respiration, these transcription factors are especially important for βcell function [24]. Therefore the goal of this study was to determine the effect of flavanol
fractions on glucose stimulated insulin secretion, and to define the mechanism by which these
compounds exert their effects.
2. Materials and Methods
2.1 Animal Husbandry and Islet Isolation
Wistar rat breeding pairs were purchased from Harlan and maintained on standard chow diet
(Teklad 7001; Harlan). Pups were weaned at 21 days. Male rats were allowed to feed ad libitum
and were maintained on a 12-hour light-dark cycle. Rats were age- and weight-matched for all
islet experiments. Pancreatic islets were isolated from 5-week-old male rats as previously
described [25-28]. Primary rat islets were cultured in RPMI 1640 and supplemented with 10%
FBS, 1% Fungizone antimycotic (Life Technologies), and 1% HEPES. Islet medium was
changed every 24 hours. All animal studies were approved and performed in accordance with
Brigham Young University’s IACUC guidelines (Protocol #16-0902).
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2.2 Cocoa Extraction and Fractionation
We selected fractionation in order to examine the activities of groups of compounds together, as
opposed to individually, due to the scarcity of commercial standards for procyanidins larger than
tetramers. A flavanol-rich cocoa extract was produced from commercially available cocoa
powder, and fractionated into monomeric catechin-rich, oligomeric procyanidin-rich and
polymeric procyanidin-rich fractions. The production and composition of these fractions has
been described previously [9]. Detailed methodologies are presented in Supplementary
Information. Characterization and enrichment levels of monomeric catechins and procyanidins in
the extract and individual fractions are presented in Supplementary Material (Table S1, Figures
S1-S2). Briefly, the whole cocoa extract is rich in monomeric catechins and oligomeric and
polymeric procyanidins extracted from cocoa. The catechin monomer-rich fraction is highly
enriched for catechin monomer species [particularly (-)-epicatechin and (±) catechin] and
depleted of procyanidins compared to the whole cocoa extract. The oligomeric procyanidin-rich
fraction is highly depleted of monomers compared to CE, but was greatly enriched for dimeric
through hexameric procyanidins compared to the whole cocoa extract. Finally, the polymeric
fraction was highly depleted for catechin monomers and dimeric through hexameric
procyanidins, and highly enriched in polymeric procyanidins (heptameric and above).
2.3 Cell Culture
The INS-1 derived 832/13 rat insulinoma cell line was maintained in complete RPMI 1640
medium with L-glutamine and 11.2 mM glucose supplemented with 50 U/ml penicillin, 50 μg/ml
streptomycin, 10 mM HEPES, 10% fetal bovine serum, and INS-1 supplement, as previously
described [29]. For all glucose-stimulated insulin secretion, RT-PCR, western blotting,
respiration and biochemical assays, cells were plated at 0 hours, cocoa extract/fractions or
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DMSO treatment were given at 24 hours, and cells were harvested following 24 hours of
treatment. Stock solutions of whole cocoa extract, monomeric, polymeric and oligomeric
catechin fractions were diluted in DMSO at a concentration of 25 mg/ml. Final treatment
concentrations for cell culture were 0-25 µg/ml whole cocoa extract/fractions or DMSO alone for
control, using 1µl DMSO/ml media or less in all conditions. The final concentration of DMSO in
media was 0.1% v/v [30]. The concentrations of individual compounds in the highest
concentration are shown in Supplementary Information (Table S2). Concentrations of individual
compounds ranged from not detectable to 2600 nM (in the highest dose employed), and were
generally on the order of 10-500 nM. The only compound to exceed 1000 nM (1 µM) was
epicatechin in the cocoa monomer fraction. The concentrations of catechin/epicatechin are
feasibly obtainable in circulation following consumption of cocoa/chocolate (up to 2-3 µM
epicatechin as the major bioavailable species) [31]; concentrations of larger species
(procyanidins greater than trimers) are likely on the high end of what that is obtainable in
circulation. However, all concentrations are generally lower than concentrations used in flavanol
cell culture studies (typically 1-50 µM).
2.4 Glucose-Stimulated Insulin Secretion.
Glucose-stimulated insulin secretion (GSIS) was performed as previously described [29].
Briefly, cells were grown to confluency, washed with PBS and preincubated in secretion assay
buffer (SAB) for 1.5 hours (114 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4 1.16 mM MgSO4, 20
mM HEPES, 2.5 mM CaCl2, 0.2% BSA, pH 7.2) containing 2.5 mM glucose. glucose-stimulated
insulin secretion (GSIS) was performed by incubating quadruplicate replicate wells of cells
cultured with varying levels of cocoa monomer fraction, oligomer fraction, polymer fraction,
whole cocoa extract or DMSO vehicle control (1 μl DMSO/ ml media for cocoa extract and

64

fractions, as well as DMSO control) in SAB containing 2.5 mM glucose for 1 hour, followed by
1 hour in SAB with 16.7 mM glucose, followed by collection of the respective buffers, as
previously described. For total insulin content, cells were lysed in RIPA buffer with protease
inhibitors (Life Technologies). Secreted insulin and total insulin was measured in SAB using a
rat insulin RIA kit (MP Biomedicals) as previously described [29, 32]. Insulin secretion from
isolated rat islets was completed as previously described [29, 32, 33].
2.5 Oroboros Respiration
Experiments were done with permeabilized INS-1 832/13 cells cultured with cocoa monomer
using a Clarke Oxygen electrode high-resolution respirometer (Oxygraph-2K; Oroboros
Instruments, Innsbruck, Austria). For permeabilization, 832/13-derived cells were harvested in
MiR05 respiration media (0.5 mM EGTA, 3 mM MgCl2, 60 mM K-lactobionate, 20 mM
taurine, 10 mM KH2PO4, 20 mM HEPES, 110 mM sucrose, and 1 g/l BSA, pH 7.1) [34, 35]. All
experiments were run in pairs with a cocoa monomer treated sample (25μg/ml at 1μl DMSO/ml
media) and a corresponding DMSO control (1 μl DMSO/ ml media). Respiration experiments
were done with an oxygen concentration ranging between 250 and 300 nmol/ml at 37°C [36]. A
basal, nonphosphorylating respiratory state (GM-Glutamate and Malate) was determined in the
presence of Glutamate (10 mM) and Malate (2 mM). The respiratory capacity of mitochondria in
the ADP-stimulated state of oxidative phosphorylation was assessed upon the addition of ADP
(2.5 mM; GMD-Glutamate and Malate and ADP) and succinate (10 mM; GMDS-Glutamate and
Malate and ADP and Succinate). Mitochondrial integrity was tested by adding cytochrome c (10
μM). Uncoupled respiratory capacity of the electron transfer system was measured after a
stepwise addition of 0.5 μM FCCP (FCCP). Residual oxygen consumption was determined
following inhibition of complex III with the addition of rotenone and antimycin A. This state of
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residual oxygen consumption served as a baseline correction for all of the other states [36].
Respiratory control ratio (RCR) was determined by dividing the GMD value by the GM value.
Analysis of complex-supported mitochondrial respiration specifically involving succinate (10
mM) was completed with the addition of rotenone (0.5 μM) for complex II-mediated leak
respiration and then ADP (2.5 mM) addition for complex II-mediated oxidative phosphorylation.
Finally, maximal electron transport system-supported respiration via complex II was determined
by the addition of FCCP (0.05 μM). All data were normalized to protein content of each
chamber, determined by BCA assay.
2.6 MTT Assay
INS-1 832/13 cells were plated in 96 well plates at a concentration of 2 x 105 cells/ml. Cells were
treated with or without cocoa monomer. After 24 hours of exposure cells underwent MTT assay
following protocols as outlined elsewhere [37, 38]. Relative absorbance was measured with a
BioTek Synergy 2 plate reader and normalized to total protein content by BCA.
2.7 Alamar Blue Assay
INS-1 832/13 cells were plated in 96 well plates at a concentration of 2 x 105 cells/ml. Cells were
treated with or without cocoa monomer. After 24 hours of exposure cells underwent Alamar
Blue assay following protocols in use by our research group [37, 38]. Relative absorbance was
measured with a BioTek Synergy 2 plate reader and normalized to total protein content by BCA.
2.8 MitoTracker Assay
INS-1 832/13 cells were plated in 96 well plates at a concentration of 2 x 105 cells/ml. Cells were
treated with or without cocoa monomer. After 24 hours of exposure were loaded with 25 nM
MitoTracker Red CMXRos-FM for 15 min, following the manufacturer's protocol (Life
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Technologies). Relative mitochondrial content was measured by fluorescence in a BioTek
Synergy 2 plate reader and normalized to total protein content by BCA.
2.9 ATP Assay
INS-1 832/13 cells were treated with or without cocoa monomer for 24 hours. Following
exposure, cells were cultured in SAB buffer with 2.5mM glucose for 2 hours, washed and then
transferred to SAB buffer with either 2.5mM glucose or 16.7mM glucose for 1 hour. Cells were
harvested and ATP content was measured by using the ATP determination kit, following the
manufacturer's specifications (Molecular Probes) [38].
2.10 HPLC GSH Assay
To assay the glutathione (GSH), glutathione disulfide (GSSG) and cellular GSH redox states
(Eh), we measured GSH and GSSG concentrations by HPLC as S-carboxymethyl, N-dansyl
derivatives using γ-glutamyl-glutamate as an internal standard as previously described [39, 40].
Cells were washed with cold PBS and the collected in cold 5% perchorlic acid buffer containing
10 µM γ-glutamyl-glutamate, used as an internal standard. Protein pellets were measured via
BCA protein assay methods for sample to sample normalization as described elsewhere [41].
Samples were subsequently derivatized, analyzed by HPLC, and intracellular GSH and GSSG
levels were determined by comparison with the internal standard. Concentrations were then used
in the Nernst equation to determine the GSH/GSSG Eh.
2.11 Apoptosis Assay
INS-1 832/13 cells were cultured in the presence or absence of cocoa monomer for 72 hours.
During the last 18 hours of culture, cells were exposed to 1mM palmitate or control
media. Percent cell viability was determined by dividing the number of cells counted for the
cocoa monomer untreated and treated groups after palmitate exposure by the number of cells
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counted with vehicle treatment after the respective treatment with or without cocoa monomer
(i.e. [Cell countCM+Palmitate]/[Cell countCM-Palmitate]) as previously described [32, 37].
2.12 Nrf2 Immunocytochemistry
INS-1 832/13 cells were seeded on poly-D-lysine coated coverslips (BD). Cells were cultured in
the presence or absence of cocoa monomer fraction for 24 hours. Cells were fixed in 4% PFA,
permeabilized with 0.5% Triton-X 100 PBS. Cells were stained for insulin (1:1,000, DAKO),
Nrf2 (1:500, GeneTex) and DAPI. Cells were imaged using 40x magnification using an Olympus
BX43 microscope with an Olympus U-HGCLGPS light source. Images were combined using
Photoshop and quantified using ImageJ (NIH).
2.13 Immunoblot Analyses
INS-1 832/13 cells were cultured in the presence or absence of cocoa monomer fraction for 24
hours. Following culture, cells were harvested and lysed in 100 μL RIPA buffer with protease
inhibitors (Life Technologies). Clarified cell lysates were run on 10% PAGE gels and transferred
to poly (vinylidene fluoride) membranes. Membranes were probed using the total OXPHOS
Complex Monoclonal Antibody cocktail (1:1000, ThermoFisher). Sheep anti-mouse (1:10,000)
and goat anti-rabbit (1:10,000) antibodies (GE Healthcare) coupled to peroxidase were used to
detect the primary antibodies. For nuclear and cytoplasmic extracts, cells were processed using
the NE-PER Nuclear Lysate Kit (Pierce) per the manufacturer's instructions. Clarified lysates
were run on 10% PAGE gels and transferred to poly (vinylidene fluoride) membranes.
Membranes were probed with diluted antibodies raised against Nrf2 (1:500, GeneTex), Histone
H3 (1:1,000, Cell Signaling) and γ-tubulin (1:1000, DSHB). Sheep anti-mouse (1:10,000) and
goat anti-rabbit (1:10,000) antibodies (GE Healthcare) coupled to peroxidase were used to detect
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the primary antibodies. Blots were developed with ECL advance reagent (GE Healthcare).
Quantitation of immunoblots was performed using ImageJ (NIH).
2.14 Quantitative RT-PCR
RNA was harvested using TriReagent (Life Technologies) and cDNA was synthesized using the
High-Capacity cDNA Reverse Transcription kit (Life Technologies), per the manufacturer's
instructions [29, 32, 38]. Real-time PCR was performed using the Life Technologies One Step
Plus Sequence Detection System and Software (Life Technologies). SYBR green based
PrimeTime assays (IDT) were used to detect rat Hmox1, Gclc, Nqo1, Nrf1, GABPA, Nrf2,
Nr4a1, Nr4a2, Nr4a3 and peptidylprolyl isomerase A (PPIA, internal control). All primer
sequences are available upon request.
2.15 Statistical Analysis
For analysis between two groups, Student's t-test was used, and differences were considered
significant when P < 0.05. One-way analysis of variance (ANOVA) was used in experiments that
had three or more groups. Differences within ANOVA were determined using Tukey's post hoc
tests, and differences were considered significant when P < 0.05. All data are reported as means
± SD.
3. Results
3.1 Cocoa monomeric fraction enhances glucose-stimulated insulin secretion in INS-1 832/13 βcells and primary rat islets.
Various studies have suggested that cocoa-derived compounds help maintain
normoglycemia. Catechins are particularly abundant in cocoa and catechin-rich supplements
have been the focus of these studies [12]. Recent studies, however, have demonstrated that cocoa
flavanols of different polymerization levels (i.e. catechins and procyanidins) have different
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effects in terms of their impact on the phenotypes characteristic of T2D [9]. Therefore, based on
these recent results, we sought to determine the effect of cocoa flavanols, fractionated based on
degree of polymerization, on glucose-stimulated insulin secretion. We cultured INS-1 832/13derived β-cells in the presence of unfractionated cocoa extract, or cocoa extract fractionated to
enrich for monomeric catechins, oligomeric procyanidins or polymeric procyanidins. The 832/13
β-cells were cultured in the presence of serial dilutions of total cocoa extract, or the three
fractions. An increase in glucose-stimulated insulin secretion versus the control was observed
with 25ug/ml for the monomeric fraction (Figure 2A). Interestingly, treatment with the cocoa
extract, oligomeric and polymeric fractions all resulted in a decrease in insulin secretion (Figure
2B-D). No change in total insulin content was observed for the monomer or polymer treated
cells, with small decreases in content for the oligomer and cocoa extract treated cells (Figure 2EH). Finally, as the highest dose of the monomer fraction was the only effective treatment for
enhancing insulin secretion, we cultured primary rat islets in 25ug/ml cocoa monomer fraction
for 24 hours, and measured the insulin secretion rate. A significant increase in insulin secretion
was observed (Figure 2I) without changes in insulin content (Figure 2J). These data demonstrate
that INS-1 832/13 β-cells or primary rat islets cultured with cocoa monomer fraction have
enhanced glucose-stimulated insulin secretion. Therefore, we focused on this fraction for the
remaining experiments.
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Figure 2 -Culture of INS-1 832/13 β-cells or primary rat islets with monomeric catechin-rich cocoa fraction
enhances glucose-stimulated insulin secretion. Glucose-stimulated insulin secretion was measured after culturing
INS-1 832/13 β-cells for 24 hours in (A) monomeric catechin-rich cocoa fraction, (B) oligomeric procyanidin-rich
cocoa fraction, ( C ) polymeric procyanidin-rich cocoa fraction and (D) whole cocoa extract with concentrations
from 0.75-25 ug/ml. Total cellular insulin content was measured after culturing INS-1 832/13 β-cells for 24 hours in
(E) monomeric catechin-rich cocoa fraction, (F) oligomeric procyanidin-rich cocoa fraction, (G) polymeric
procyanidin-rich cocoa fraction and (H) whole cocoa extract with concentrations from 0.75-25 ug/ml. glucosestimulated insulin secretion (I) and total insulin content (J) was measured from primary rat islets cultured in the
presence or absence of 25 ug/ml cocoa monomer fraction. n=4 individual replicates per conditions, run in
quadruplicate for each replicate. * p<0.05 vs. control. For ANOVA (Figure 2A-H), means sharing the same letter are
not significantly different from the control (p>0.05) or means that have no letter in common are significantly
different from the control (p<0.05)
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3.2 Cocoa monomer fraction treatment enhances β-cell mitochondrial respiration and ATP
production.
Insulin secretion is directly connected to mitochondrial respiration. Therefore, we
hypothesized that the increase in glucose-stimulated insulin secretion could be due to enhanced
mitochondrial respiration. We sought to determine if culturing INS-1 832/13 β-cells with the
cocoa monomer fraction would affect β-cell mitochondrial respiration. Treatment of INS-1
832/13 β-cells with the cocoa monomer fraction resulted in significantly increased respiratory
function in GM, GMD, GMDS and FCCP respiratory measurements (Figure 3A). This increase
was not due to increased complex II (CII)-mediated respiration (Figure 3B), nor were significant
differences in mitochondrial “health” observed (Figure 3C), as determined via respiratory control
ratio (RCR). Finally, these results were substantiated by increased levels of ATP observed after
culturing INS-1 832/13 β-cells with the cocoa monomer fraction under stimulatory conditions
(16.7mM glucose) with no change under non-stimulatory conditions (2.5mM) (Figure 3D).
Taken together, these data demonstrate an overall favorable alteration in mitochondrial
physiology; namely, increased respiration associated with enhanced ATP formation.
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A.

B.

C.

D.

Figure 3 -Culture of β-cells with monomeric catechin-rich cocoa fraction enhances mitochondrial respiration and
function. Mitochondrial respiration (A) was measured in INS-1 832/13 β-cells following 24 hours of culture with 25
ug/ml a monomeric catechin-rich cocoa fraction. GM-glutamate and malate, GMD-glutamate, malate and ADP,
GMDS-glutamate, malate ADP and succinate, and FCCP-Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
(uncoupling reagent). No significant changes were observed in the complex II respiration (CII Factor, B) or in the
overall mitochondrial health as measured by RCR ( C ). (D) Total cellular ATP was measured in INS-1 832/13 βcells following 24 hours of culture with 25 ug/ml monomeric catechin-rich cocoa fraction and exposure to either
unstimulatory (2.5mM) or stimulatory (16.7mM) levels of glucose. n=4 individual replicates per conditions. *
p<0.05, **p<0.01 vs. control.
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3.3 Cocoa monomer-induced enhancement of β-cell mitochondrial respiration is not due to
increased mitochondrial viability or mitochondrial content.
The observed increase in mitochondrial respiration could be due to increased
mitochondrial viability or increased mitochondrial content. To determine if mitochondrial
viability was enhanced, we used the Alamar Blue and MTT assays. Neither assay, however,
demonstrated any increase in viability due to culture with the cocoa monomer fraction (Figure
4A-B). To determine if total mitochondrial content was increased, we stained the cells with the
fluorescent mitochondrial-specific stain MitoTracker Red. Total fluorescence of the samples
demonstrated no significant differences between the two groups on a per cell basis (Figure 4C).
These data indicate that culture of INS-1 832/13 β-cells with cocoa monomer fraction does not
increase mitochondrial viability or mitochondrial number.
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A.

B.

C.

Figure 4 -Culture of β-cells with monomeric catechin-rich cocoa fraction does not improve mitochondrial respiration
or function through increased mitochondrial viability or mitochondrial number. No differences in mitochondrial
viability were observed after culturing INS-1 832/13 β-cells with a monomeric catechin-rich cocoa fraction as
measured by (A) Alamar Blue or (B) MTT staining. No differences in total mitochondrial content were observed by
( C ) MitoTracker staining of INS-1 832/13 β-cells cultured with monomeric catechin-rich cocoa fraction. n=4
individual replicates per conditions.
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3.4 Culture of β-cells with cocoa monomers increases levels of mitochondrial complex proteins.
The enhanced mitochondrial respiration observed in INS-1 832/13 β-cells cultured in the
presence of cocoa catechin monomers could be due to enhance mitochondrial function.
Therefore, we measured the expression of mitochondrial complexes in INS-1 832/13 β-cells after
culturing in the presence or absence of cocoa monomer fraction for 24 hours. A significant
increase was observed in the protein levels of mitochondrial respiratory complex III, IV and V,
while no significant changes were observed for complex I or II (Figure 5A-B). The significant
increase in complex V and the lack of change in complex II levels substantiate the findings
regarding ATP levels and CPII factor. These results strongly suggest that culture of INS-1
832/13 β-cells with cocoa catechin monomers results in increased insulin secretion due to
increased ATP production and mitochondrial respiration through the increased expression of
components of the electron transport chain.
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A.

B.

Figure 5 -Culture of β-cells with monomeric catechin-rich cocoa fraction increases electron transport chain complex
V, III and IV levels. Mitochondrial electron transport chain complex levels (A) were measured by western blotting
and quantified (B) demonstrating increased levels of complex V, IV and III. n=3 individual replicates. * p<0.05,
***p<0.001, ****p<0.0001 vs. control.
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3.5 Culture of β-cells with cocoa monomer fraction initiates an antioxidant response.
Previous studies have suggested that cocoa flavanols act as mild oxidants to initiate an
antioxidant response [42]. To verify these findings, we measured potential changes in Eh, GSH
and GSSG levels, as well as any potential apoptotic protection the monomeric fraction might
confer in the presence of palmitate. INS-1 832/13 cells cultured with cocoa monomer fraction
improved the cellular redox state (Figure 6A). Furthermore, these cells had elevated levels of
GSH (Figure 6B) while maintaining the cellular GSSG levels (Figure 6C). This, however, does
not impede cellular proliferation rates (Figure 6D), indicating that treatment of 832/13 cells with
cocoa monomer fraction does not decrease cellular viability. Finally, it has been shown that
culture of β-cells in the presence of 1.0 mM palmitate induces apoptosis through reactive oxygen
species production. Therefore, we determined the susceptibility of 832/13 cells to palmitateinduced apoptosis after culturing in the presence of cocoa monomer for 72 hours. We observed
that the monomeric fraction attenuated palmitate-induced apoptosis. (Figure 6E). These data
suggest that culture with the cocoa monomer fraction promotes an antioxidant response capable
of protecting β-cells from apoptotic stimuli.
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B.

A.

D.

C.

E.

Figure 6 -Culture of β-cells with monomeric catechin-rich cocoa fraction improves cellular redox potential through
increased GSH levels, and results in increased protection against ROS induced apoptosis. INS-1 832/13 β-cells
cultured for 24 hours with 25 ug/ml monomeric catechin-rich cocoa fraction have improved cellular redox potential
(A). Increased GSH levels (B) were observed while GSSG levels (C) remained constant. Culture with monomeric
catechin-rich cocoa fraction (D) maintains 832/13 β-cell proliferation, and (E) protects against palmitate induced
apoptosis. n=6 individual replicates. ****p<0.0001 vs. control.
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3.6 Culture of β-cells with cocoa monomer fraction leads to nuclear translocation and activation
of Nrf2.
Increased glutathione levels and improved cellular redox states are indicative of the
activation of the transcription factor Nrf2. Under normal conditions, Nrf2 is bound by KEAP1 in
the cytosol where it is constantly degraded through the proteasome. However, under conditions
of oxidative stress, Nrf2 is released from KEAP1, is allowed to translocate to the nucleus, and
induces expression of target genes involved in glutathione production, reactive oxygen species
(ROS) quelching and NAD(P)H cycling. The increased glutathione levels and an improved
cellular redox state are suggestive of Nrf2 nuclear translocation and transcriptional
transactivation. To determine if Nrf2 is migrating to the nucleus we performed
immunofluorescence assays (Figure 7A). These studies demonstrate that Nrf2 staining after 24
hours of culture with cocoa monomer fraction results in increased nuclear localization.
Furthermore, nuclear and cytosolic fractionation demonstrate that a significantly increased level
of Nrf2 is observed in the nucleus of cocoa monomer fraction treated 832/13 β-cells (Figure 7BE). Finally, expression of three hallmark Nrf2 target genes, Hmox1, Gclc, and Nqo1, were all
uprgegulated (Figure 7F-H). These data demonstrate that culture of INS-1 832/13 β-cells with
cocoa monomer fraction results in nuclear migration and activation of Nrf2.
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Figure 7 -Culture of β-cells with monomeric catechin-rich cocoa fraction induces nuclear localization and
transcriptional activation of Nrf2. INS-1 832/13 β-cells cultured for 24 hours with 25 ug/ml monomeric catechinrich cocoa fraction have increased Nrf2 nuclear localization as measured by (A) immunoflorescence staining of
treated and untreated INS-1 832/13 β-cells, (B, D) western blotting of cytoplamsic and (C,E) nuclear fractions, and
increased expression of Nrf2 target genes (F) Hmox1 (G) Gclc and (H) Nqo1. For immunoflorescence assay n=5 per
condition, for western blotting n=4 per condition, for RT-PCR assays n=6 per condition. * p<0.05, **p<0.01 vs.
control.
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3.7 Culture of β-cells with cocoa monomer fraction leads to increased expression of genes
responsible for mitochondrial complex biogenesis.
Recent studies have begun to define the Nrf2 target genes. Among the genes that have
been defined as targets of Nrf2 is the transcription factor Nrf1. Nrf1 and GABPA are known as
the nuclear respiratory factors and are critical for upregulation of metabolic enzymes necessary
for mitochondrial respiration. Therefore, given the connection between Nrf2 and Nrf1, and the
increase in mitochondrial electron transport chain components, we measured expression of Nrf1,
GABPA and Nrf2. Our results demonstrate that culture with cocoa monomer fraction results in
increased expression of both Nrf1 and GABPA (Figure 8A-B). Interestingly, our results also
demonstrated increased expression of Nrf2 (Figure 8C), suggesting that this cycle may continue
as long as the 832/13 β-cells remain exposed to cocoa monomer fraction. Finally, we have
previously shown that the orphan nuclear receptors Nr4a1, Nr4a2 and Nr4a3 are critical for βcell glucose metabolism and insulin secretion [38]. Treatment of INS-1 832/13 cells with cocoa
monomer does not induce expression of any Nr4a family members (Figure 8D-F), demonstrating
that the change in insulin secretion is independent of this previously defined pathway. These data
suggest that the increased expression of mitochondrial respiratory complexes, which ultimately
results in increased β-cell insulin secretion, is due to the nuclear migration of Nrf2 and
upregulation of NRF-1 and GABPA expression.
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Figure 8 -Culture of β-cells with monomeric catechin-rich cocoa fraction induces upregulation of the transcription
factors Nrf1 and GABPA that are essential for expression of mitochondrial electron chain components. INS-1
832/13 β-cells cultured for 24 hours with 25 ug/ml monomeric catechin-rich cocoa fraction have increased
expression of the nuclear respiratory factors (A) Nrf1 and (B) GABPA. Furthermore, expression of ( C ) Nrf2 is also
increased after culture conditions. No change was observed for the orphan nuclear receptors (D) Nr4a1, (E) Nr4a2,
and (F) Nr4a3, which have been shown to play a role in glucose metabolism and β-cell insulin secretion. n=8 per
condition, each run in triplicate. **p<0.01, ***p<0.001 vs. control.
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4. Discussion
Over 9% of the American population has T2D and with over 1.7 million new cases each
year, it is proving to be a significant healthcare concern [43]. While T2D is initially
characterized by decreased insulin sensitivity in peripheral tissue, progression of the disease
ultimately leads to destruction of pancreatic β-cells [44, 45]. Strategies that improve the insulin
secretion rate or promote β-cell viability have direct application in first preventing T2D
progression by inhibiting β-cell destruction, as well as treating patients suffering with prolonged
T2D. Mitochondrial function is vital to the functionality and viability of pancreatic β-cells, with
glucose-stimulated insulin secretion relying on mitochondrial respiration through the
components of the electron transport chain [46].
Recent studies have found that cocoa flavanols may improve glucose homeostasis and
protect pancreatic β-cells from apoptotic stimuli. Interestingly, purified monomeric, oligomeric,
and polymeric cocoa flavanol fractions may exert different levels of benefit with regard to β-cell
function and viability. Given these findings, cocoa flavanols may represent a therapeutic option
for increasing functional β-cell mass.
The purpose of this study was to 1) determine the effect of different cocoa flavanol
fractions on β-cell function and 2) identify potential mechanisms underlying these effects. We
have shown that a cocoa monomer-rich fraction enhances glucose-stimulated insulin secretion
and have identified a potential mechanism of action explaining this effect. We show that 24-hour
cocoa monomer treatment of 832/13 β-cells is sufficient to initiate Nrf2 translocation to the
nucleus, leading to upregulation of antioxidant genes as well as those vital to mitochondrial
biogenesis (Figure 9). This is consistent with previous studies showing that flavanol
consumption may increase mitochondrial copy number in skeletal muscle [47]. These data were
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substantiated as we saw increased glutathione levels as well as increased levels of mitochondrial
complexes III-V after administration of the monomer fraction. Cocoa monomer treatment led to
higher levels of ATP, which would be expected with improved mitochondrial function and
enhancement of insulin secretion. These data provide the first definitive mechanism by which
cocoa monomeric catechins enhance insulin secretion in the β-cell.
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Figure 9 -Monomeric cocoa catechins enhance β-cell glucose-stimulated insulin secretion. Exposure of β-cells to a
monomeric catechin-rich cocoa fraction results in 1) oxidation of KEAP1 which releases Nrf2, 2) nuclear
translocation of Nrf2, 3) transcriptional activation of Nrf2 targets such as Nqo1, Gclc, Hmox1, Nrf1, GABPA and
Nrf2. This results in 4) a more reduced redox state, increased glutathione concentrations, increased ROS
detoxification and improved NAD(P)/NAD(P)H cycling. Upregulation of Nrf1 and GABPA results in 5) induction
of the electron chain components complex V, III and IV. Increased expression of these integral mitochondrial
components 6) enhances mitochondrial respiration resulting in 7) increased cellular ATP levels and 8) ultimately
increased levels of glucose-stimulated insulin secretion.
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Our data in this study demonstrate that monomeric catechin-rich cocoa fraction enhance
insulin secretion. Previously published research from our group demonstrated that only
oligomeric flavanol cocoa fractions normalize blood glucose levels in C57Bl/6J mice fed a 12week high fat diet. This apparent discrepancy in findings may be a function of the method used
to induce T2D in the animal model. In T2D, hyperglycemia has been shown to initially be a
result of peripheral tissue insulin resistance, with β-cell loss coming after long-term
hyperglycemia and hyperlipidemia. It is likely that 12 weeks of high fat feeding was sufficient to
induce peripheral insulin resistance, however the duration was not enough to cause β-cell
derangement. High fat diet feeding of C57Bl/6J mice has been used to induce the phenotypes of
T2D, however the length of time necessary for different phenotypes associated with T2D varies.
Feeding times of 16-20 weeks are recommended to observe obesity, insulin resistance, and β-cell
defects. This is supported by two recent studies, where 12-14 weeks of high fat feeding of
C57Bl/6J mice resulted in the presence or absence of insulin secretion defects. Since our
previous study did not directly measure β-cell insulin secretion or mass, we are unable to
determine if β-cell defects were present after the feeding regimen. Future studies to translate our
findings into a T2D model with β-cell dysfunction are planned.
In addition, our data demonstrate that culture of the INS-1 832/13 cells with the
oligomeric, polymeric and cocoa extract resulted in decreased glucose stimulated insulin
secretion. As the purpose of this study was to determine if insulin secretion could be enhanced,
we have not yet pursued a mechanism by which culture with the three other fractions inhibited
insulin secretion. These studies are currently ongoing.
Our data demonstrate Nrf2 nuclear localization after culture with cocoa monomer. Nrf2 is
typically found in the cytosol bound to Keap1. When confronted with reactive oxygen species,
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Nrf2 can be liberated to migrate to the nucleus and upregulate transcription of antioxidant genes.
Flavanols have been shown to present a mild generation of reactive oxygen species [48]. This
relatively small oxidative burden can lead to disruptive interactions with Keap1 cysteine thiol
bonds, allowing Nrf2 translocation and initiation of an antioxidant response. It is important to
note, however, that Nrf2 translocation can be induced through non-oxidative stress mediated
pathways. MAPKs and PI3K have both been shown to phosphorylate Nrf2 and mediate its
nuclear translocation [49]. Furthermore, INS-1E cells cultured with epicatechin have been shown
to induce no increase in reactive oxygen species [50]. While our data clearly show that Nrf2
translocates to the nucleus, our data do not define the mechanism by which this occurs.
Therefore it is possible that monomeric catechins activate MAPKs or PI3K which results in Nrf2
phosphorylation, stabilization and nuclear localization.
In addition to ARE-promoter binding and subsequent upregulation of antioxidant genes,
Nrf2 has been shown to upregulate NRF-1 and GABPA, integral transcription factors in
mitochondrial biogenesis [51-54]. Activation of NRF-1, in particular, has shown to be sufficient
to induce mitochondrial biogenesis through significant upregulation of Tfam [22, 23, 55, 56].
An exciting finding of this paper is that the monomeric fraction was found to have the
greatest bioactivity in β-cells, compared to the larger procyanidins. This is particularly important,
given the fact that monomeric flavanols have much greater oral bioavailability than oligomeric
and polymeric forms [57-59]. Therefore, the finding that the most bioavailable cocoa flavanols
are also the most bioactive in this context suggests great potential for translation from in vitro
cell culture to in vivo efficacy in animals and humans. While our data clearly show an effect of
monomeric flavanols, they do not negate the possibility that the larger unabsorbed dietary
flavanols may still have systemic effects due to their transformation to bioavailable microbial
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metabolites by the commensal gut microbiota[60-62]. Therefore, while monomeric cocoa
flavanols appear to have the greatest impact on β-cell function of the native flavanols, the impact
of these microbial metabolites remains unknown. These metabolites have been identified as a
potential “missing link” between dietary polyphenols with potent activities despite poor systemic
bioavailability[63]. Therefore, investigations are warranted to elucidate whether the systemic
impacts of these cocoa flavanols in vivo, particularly the larger compounds, are mediated by
microbial biotransformation in the gut. These studies are currently ongoing.
As has been noted, prolonged T2D is characterized by a reduction in functional β-cell
mass. While insulin therapy is the predominant treatment, islet transplantation has shown
promise along with pharmacological intervention aimed at preserving and enhancing residual βcell mass. We have demonstrated that this cocoa monomer fraction promotes β-cell stability and
enhances function through upregulation of key genes encoding antioxidant and mitochondrial
respiratory complex proteins. These pathways could be leveraged to provide ex-vivo islet
expansion and transplantation or cocoa-derived medications that enhance insulin secretion. In
this way, cocoa flavanols may provide a novel approach to ameliorating the effects of T2D.
Disclosure
The authors have declared no conflict of interest.
Acknowledgments
The authors would like to thank Drs. Joshua L. Andersen and Jason D. Kenealey,
Brigham Young University, Provo, Utah for their guidance and discussion regarding the
presented research. We thank all members of the Tessem laboratory for constructive discussion
and analysis of data. We thank the American Diabetes Association (1-17-IBS-101 to JST), the

91

Diabetes Action Research and Education Foundation (grant to JST), BYU MEG program (grant
to JST) and the BYU ORCA program (grant to BFB) for funding.

92

FUTURE DIRECTION
Having found that monomeric cocoa catechins enhance glucose-stimulated insulin
secretion at a concentration of 25 ug/mL, our recent study focused on that concentration with
regard to other aspects of beta cell function, such as proliferation and protection against
apoptosis-inducing facors. Currently, our research group is investigating the effects of a wide
range of cocoa monomer, oligomer, polymer fraction and whole cocoa extract concentrations on
beta cell proliferation and protection against palmitate. This will provide a broader understanding
of the impact of different cocoa fractions on functional beta cell mass. Such knowledge could
then be leveraged in applications such as ex-vivo islet expansion, where researchers could treat
transplant-ready islets with an ideal concentration of a beneficial cocoa fraction in order to
increase the amount of available islets for T2D patients.
Oligomeric and polymeric procyanidins did not enhance glucose-stimulated insulin
secretion in this study, but our research group has shown in previous in vivo studies that these
larger fractions are associated with greater protection against diabetes onset when compared to
monomeric forms. Although monomeric cocoa catechins have a much higher bioavailability than
larger cocoa fractions, their effect in vivo could be explained by their transformation to
bioavailable metabolites by microbiota in the gut. To pursue this theory, our research group is
currently investigating the impact of different cocoa breakdown metabolites on beta cell viability
and function.
Transition to animal studies represents the next step in assessing the impact of various
cocoa fractions on diabetic symptoms in vivo.
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MATERIALS AND METHODS
All methods were originally described in Dorenkott et al. [1].
Cocoa Flavanol Extraction. A flavanol-rich cocoa extract (CE) was produced following the
methods of Adamson et al. [2] and Robbins et al. [3] with modifications. Commercially-available
non-alkalized natural cocoa powder (The Hershey Co., Hersey, PA) was defatted by dispersing
100 g cocoa powder in 400 mL hexane, sonication (10 min), stirring (5 min) and centrifugation (5
min, 20 °C, 5,000 x g). The supernatant was discarded and the extraction repeated. Residual hexane
was evaporated from defatted cocoa at room temperature. Flavanols were extracted by dispersing
defatted cocoa in 400 mL acetone: water: glacial acetic acid (70:28:2 v/v/v) solution, sonication
(10 min), stirring (5 min) and centrifugation (5 min, 20 °C, 5,000 x g). The supernatant was
collected and the extraction was repeated. The supernatants were pooled, acetone was evaporated
using a rotary evaporator (40-45 °C), and the remaining extract (predominantly water) was frozen
at −80 °C and freeze-dried for ≥2 d. After freeze-drying, CE was crushed into a powder, weighed,
and stored at −80 °C. The final extraction yield from 100 g cocoa powder was ~12.8 g CE.
Cocoa Extract Fractionation. CE was fractionated by solid phase extraction to produce three
fractions with different mDP values (monomers, oligomers, and polymers) according to the
method used by Sun et al. [4] with modifications. A tC18 Sep-Pak SPE column (20 cc, 5 g sorbent)
(Waters, Milford, MA) was attached on top of a C18 Sep-Pak SPE column (20 cc, 5 g sorbent). The
columns were preconditioned with 10 mL methanol (MeOH) followed by 10 mL distilled,
deionized water (ddH2O, pH 7.0) on a vacuum manifold. CE was dissolved in acetone: water:
glacial acetic acid (70:28:2 v/v/v) to 0.1 g/mL and 1.5 mL of the CE solution was loaded onto the
column. Highly polar compounds (primarily phenolic acids) were eluted with 10 mL ddH2O and
discarded. Monomers and oligomers were eluted together with 35 mL ethyl acetate, concentrated
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by rotary evaporation, and set aside. The polymer fraction was then eluted with 40 mL MeOH,
concentrated by rotary evaporation, dispersed in ddH2O and freeze-dried as described above until
a dark brown powder remained. A new set of tC18 Sep-Pak + C18 Sep-Pak columns was then preconditioned, and the combined monomer/oligomer fraction (dissolved in 1.5 mL of the acetone:
water: glacial acetic acid solution) was loaded onto the column. Monomers were eluted with 35
mL diethyl ether, concentrated by rotary evaporation, dispersed in ddH2O and freeze-dried until a
light brown powder remained. Oligomers were eluted with 40 mL MeOH, concentrated by rotary
evaporation, dispersed in ddH2O and freeze-dried until a cream-colored powder remained. All
three fractions were stored at −20 °C for 2 d, weighed, and stored −80 °C. An average of ~155 mg
monomer, ~282 mg oligomer, and ~502 mg polymer were produced from each batch of 10
replicate fractionations (a total of 15 mL containing 1.5 g CE, or 1.5 mL containing 0.15 g CE per
replicate). Fractions produced from separate batches were combined to produce a single uniform
lot of each fraction.
Normal-Phase HPLC of Cocoa Procyanidins. Cocoa fractionation was further evaluated by
normal-phase HPLC profiling [1]. Analyses were performed on an Agilent Technologies (Santa
Clara, CA) 1260 Infinity HPLC equipped with a solvent degasser, quaternary pump, an
autosampler with temperature control, a thermostat column compartment, and a fluorescence
detector (FLD). Separations were carried out using a Develosil Diol column (100 Å, 250 × 4.6
mm, 5 μm particle size) equipped with a Luna HILIC guard column (4 × 3.0 mm ID SecurityGuard
cartridge and cartridge holder) (both from Phenomenex, Torrance, CA). The column temperature
was 35°C. Binary gradient elution employing 2% acetic acid (v/v) in ACN (phase A) and 2% acetic
acid (v/v) and 3% ddH2O (v/v) in MeOH (phase B) was performed at a flow rate of 1 mL/min. The
gradient was as follows: 93% A at 0 min, 93% A at 3 min, 62.4% A at 60 min, 0.0% A at 63 min,
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0.0% A at 70 min, 93.0% A at 76 min, 7.0% B at 0 min, 7.0% B at 3 min, 37.6% B at 60 min,
100.0% B at 63 min, 100.0% B at 70 min, and 7.0% B at 76 min. FLD excitation and emission
wavelengths were 230 nm and 321 nm, respectively. CE and cocoa fractions were prepared at 10
mg/mL in acetone: water: acetic acid (70:28:2, v/v/v) immediately prior to analysis. All the
samples and standards were held at 5 °C in the autosampler before injection. Injection volume was
5 μL. Mixtures of authentic standards consisting of monomers (DP 1: C, EC, ECG), PC oligomers
(dimers-hexamers), and PC polymers (heptamers-decamers) were prepared and used as a reference
for comparison of elution profiles.
UPLC-MS/MS Analysis of Cocoa Procyanidins. CE and cocoa fractions were analyzed by UPLCMS/MS (n=3) to quantify individual monomer and procyanidin species up to decamers [1]. CE
and cocoa fractions were prepared by diluting to 0.05 mg/mL in 0.1% formic acid in water/0.1%
formic acid in ACN (95:5). UPLC separations and MS/MS analyses were performed on the
Acquity UPLC-TQD and UPLC HSS T3 column described above (2.1 mm × 100 mm, 1.8 µm
particle size). Column temperature, sample temperature, mobile phases, flow rate, gradient, ESI
parameters, MS/MS CID settings, data collection parameters, and Intellistart tuning of authentic
standards to generate MRM functions were the same as described above. MRM parameters for
monomers and PCs are listed in Table S1.
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Table S1. MS/MS Settings for MRM Detection of Monomers and Procyanidins.
MW
[M –
Daughter
Cone
tRa
H]−b
Compound
(g molIon
Voltage
(min)
1
)
(m/z)
(m/z)
(V)
procyanidin dimer B1
2.68 578.136
577.136
289.105
38
(−)-epigallocatechin
2.76 306.038
305.038
124.977
40
unknown dimer 1c
2.92 578.136
577.136
425.102
36
(±)-catechin
2.99 290.028
289.028
245.057
36
procyanidin trimer T2
3.09 866.218
865.218
289.102
36
unknown dimer 2c
3.29 578.136
577.136
425.102
36
procyanidin dimer B2
3.34 578.136
577.136
425.102
36
(−)-epicatechin
3.63 290.092
289.092
245.056
42
(−)-epigallocatechin
3.67 458.038
457.038
168.982
34
gallate
procyanidin trimer C1
3.82 866.218
865.218
287.085
46
cinnamtannin tetramer
1154.80
3.97
576.404
125.020
26
A2
8
procyanidin dimer B2
3.99 730.164
729.164
407.129
42
gallate
procyanidin octamer
4.04 2307.17
1152.58
125.17
48
unknown dimer 3c
4.07 578.136
577.136
425.102
36
procyanidin pentamer
1442.82
4.10
720.410
125.022
26
0
procyanidin hexamer
1731.03
4.23
864.519
125.020
32
8
procyanidin nonamers
4.33 2586.36
864.12
125.17
28
procyanidin heptamer
4.41 2018.80
1008.40
125.17
36
(−)-epicatechin gallate
4.60 442.076
441.076
168.968
38
procyanidin decamers
4.60 2883.55
960.18
125.17
30
procyanidin dimer B5
4.64 578.136
577.136
289.107
30
a
retention time

Collision
Energy (eV)
24
22
16
14
48
16
16
12
16
32
34
32
68
16
44
56
46
56
18
52
26

All MRMs used singly-charged parent ions except for cinnamtannin tetramer A2, pentamers, hexamers,

b

heptamers, octamers, which were doubly-charged ([M – 2H]2−), and nonamers and decamers, which were
triply-charged ([M – 3H]3−)
c

likely procyanidin dimers B3, B4, and either B6, B7 or B8

The levels of PCs with DP 1-6 in CE and cocoa monomer, oligomer, and polymer fractions are
shown in Fig. S1. CE contains moderate levels of monomers, dimers, and DP 3-6 compared to
each enriched fraction. The monomeric PC fraction is enriched for monomers and dimers, but
depleted of DP 3-6, compared to CE. The oligomeric PC fraction is depleted of monomers, but
enriched for dimers and DP 3-6, compared to CE. The polymeric PC fraction was depleted for
monomers, dimers and DP 3-6 and slightly enriched for PCs DP 7-10 compared to CE. As the
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reverse-phase UPLC analysis only quantified PCs up to DP 10, the composition of larger PCs that
make up a large portion of CE and the majority of the polymer fraction (see Fig. S2) are not
reflected in the total composition values in Fig. S1.
Normal-phase HPLC elution profiles of CE and PC fractions are shown in Fig. S2. In this method,
retention time roughly correlate to DP (larger DP elute later, see elution profiles of standards, top
of Fig. S2), confirming that monomeric, oligomeric, and polymeric fractions are enriched for
smaller, intermediate, and larger PCs, respectively. This also confirms the presence of larger PCs
in the polymeric fraction that were not detected in Fig. S1.

Figure S1. Levels of procyanidins in cocoa extract (CE) and individual cocoa fractions. Data reported as mean ± SEM
from n=3 replicates. Treatments with different letter superscripts are significantly different (P<0.05, one-way ANOVA
with Fisher’s LSD post-hoc test). Note that the polymer fraction contains the lowest levels of all groups of compounds,
since polymers were not quantified; the presence of these large, non-quantified compounds was confirmed by normalphase HPLC (see Fig. S2). Data adapted with permission from Dorenkott, Melanie R., et al. "Oligomeric cocoa
procyanidins possess enhanced bioactivity compared to monomeric and polymeric cocoa procyanidins for preventing
the development of obesity, insulin resistance, and impaired glucose tolerance during high-fat feeding." Journal of
Agricultural and Food Chemistry 62.10 (2014): 2216-2227; Copyright 2014, American Chemical Society.
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Figure S2. Fluorescence profiles (λex = 230 nm, λex = 321 nm) of normal-phase HPLC chromatograms of authentic
standards [monomers, oligomers (DP 2-6), and polymers (DP 7-10)] and the profiles of the cocoa extract, monomer,
oligomer, and polymer fractions used in the mouse diets. Note that the scale is different for each chromatogram to
emphasize relative peak heights within each trace. The scale for each chromatogram in fluorescence units (LU) is as
follows: monomer standards, 740 LU; oligomer standards, 72 LU; polymer standards, 46 LU; CE, 230 LU; monomerrich fraction, 160 LU; oligomer-rich fraction, 150 LU; polymer-rich fraction, 40 LU. Figure reproduced with
permission from Dorenkott, Melanie R., et al. "Oligomeric cocoa procyanidins possess enhanced bioactivity compared
to monomeric and polymeric cocoa procyanidins for preventing the development of obesity, insulin resistance, and
impaired glucose tolerance during high-fat feeding." Journal of Agricultural and Food Chemistry 62.10 (2014): 22162227; Copyright 2014, American Chemical Society.
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Table S2. Media concentrations of measured cocoa flavanols in the highest concentration
employed in cell culture studies (25 μg extract or fraction/mL media)
Media concentrationa
(nM)
Compound

CEb

Monomer

Oligomer

Polymer

(±)-catechin

143.9

820.4

10.3

1.1

(−)-epicatechin

508.5

2637.1

57.5

6.3

(−)-epigallocatechin

1.2

1.9

1.6

1.1

procyanidin dimer B1

15.4

20.6

48.4

0.6

procyanidin dimer B2

211.0

264.6

665.9

10.8

procyanidin dimer B5

134.1

325.2

316.5

3.6

unknown procyanidin dimer
1c

1.6

2.0

4.9

0

unknown procyanidin dimer
2c

5.0

6.8

18.7

0

unknown procyanidin dimer
3c

0

29.3

13.4

0

procyanidin trimer C1

234.4

182.1

759.0

26.9

cinnamtannin tetramer A2

76.2

49.6

229.5

11.6

procyanidin pentamers

63.9

30.0

169.3

24.3

procyanidin hexamers

39.0

0.0

52.7

31.5

procyanidin heptamersd

26.5

0.0

23.9

33.7

procyanidin octamersd

8.0

2.1

20.4

0

procyanidin nonamersd

17.2

1.4

29.3

18.1

procyanidin decamersd

0

0

0

31.9

a

25 μg extract or fraction/mL; media concentrations calculated from extract/fraction

concentrations reported in Dorenkott, Melanie R., et al. "Oligomeric cocoa procyanidins
possess enhanced bioactivity compared to monomeric and polymeric cocoa procyanidins for
preventing the development of obesity, insulin resistance, and impaired glucose tolerance
during high-fat feeding." Journal of Agricultural and Food Chemistry 62.10 (2014): 22162227; Copyright 2014, American Chemical Society.
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b
c

CE: whole cocoa extract

Likely procyanidin dimers B3, B4, and either B6, B7 or B8

d

As the reverse-phase UPLC analysis only quantified procyanidins up to DP 10, the

composition of larger procyanidins that make up a large portion of whole extract and the
majority of the polymer fraction (see Figure S2 above) are not reflected in the composition
values here.
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